adenosine monophosphate has been researched along with cangrelor in 388 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.26) | 18.2507 |
| 2000's | 99 (25.52) | 29.6817 |
| 2010's | 220 (56.70) | 24.3611 |
| 2020's | 68 (17.53) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, A; Clegg, JA; Coombs, ME; Cox, D; Dixon, J; Humphries, RG; Hunt, SF; Ingall, AH; Kindon, ND; Leff, P; McInally, JI; Smith, JA; Teobald, BJ; Tomlinson, W; Willis, PA | 1 |
| Hayakawa, T; Ishii-Watabe, A; Mizuguchi, H; Uchida, E | 1 |
| Heemskerk, JW; Sage, SO; Yamoah, EH | 1 |
| Driscoll, EM; Gonzales, ML; Huang, J; Lucchesi, BR; Park, AM | 1 |
| Cameron, KE; Heptinstall, S; May, JA; Sanderson, HM; Storey, RF; White, AE | 1 |
| Gear, AR; Suttitanamongkol, S | 1 |
| Honda, S; Imai, Y; Inoue, K; Kohsaka, S; Nakamura, Y; Ohsawa, K; Sasaki, Y | 1 |
| Maayani, S; Martinez, R; Schwarz, T; Tagliente, TM | 1 |
| Oldroyd, KG; Storey, RF; Wilcox, RG | 1 |
| Gratacap, MP; Nieswandt, B; Offermanns, S; Payrastre, B | 1 |
| Bath, P; Heptinstall, S; Zhao, L | 1 |
| McIntire, LV; Moake, JL; Turner, NA | 1 |
| Guile, SD; Ince, F; Ingall, AH; Kindon, ND; Meghani, P; Mortimore, MP | 1 |
| Balduini, C; Lova, P; Paganini, S; Sinigaglia, F; Torti, M | 1 |
| Chattaraj, SC | 1 |
| de Groot, PG; IJsseldijk, MJ; Jeninga, EH; Nurden, AT; Nurden, P; Remijn, JA; Sixma, JJ; van Willigen, G; Wu, YP | 1 |
| Covic, L; Kuliopulos, A; Singh, C; Smith, H | 1 |
| Eto, K; Goto, S; Handa, S; Ikeda, Y; Tamura, N | 1 |
| Ellborg, M; Jacobsson, F; Swahn, E; Wallentin, L | 1 |
| Heptinstall, S; Judge, HM; Storey, RF; Wilcox, RG | 1 |
| Balduini, C; Barberis, L; Hirsch, E; Lova, P; Paganini, S; Sinigaglia, F; Torti, M; Wymann, M | 1 |
| Heptinstall, S; Storey, RF; Wilcox, RG | 1 |
| Nurden, AT; Nurden, P | 1 |
| Carneiro, M; Humphries, RG; Klein, A; Lincoff, AM; Murray, D; Penn, MS; Tarakji, K; Thomas, JD; Topol, EJ; Turner, J; Wang, K; Zhou, X; Zhou, Z | 1 |
| Heemskerk, JW; Heijnen, VV; oude Egbrink, MG; Reneman, RS; Slaaf, DW; van Gestel, MA | 1 |
| Bath, PM; Fox, S; Heptinstall, S; Judge, H; Lösche, W; May, J; Zhao, L | 1 |
| Lindahl, TL; Ramström, S; Rånby, M | 1 |
| Cazenave, JP; Freund, M; Gachet, C; Leon, C; Ravanat, C | 1 |
| Grieco, G; Jonas, S | 1 |
| Behan, MW; Fox, SC; Heptinstall, S | 1 |
| Harder, S; Klinkhardt, U; Kuczka, K | 1 |
| Bryckaert, M; Habib, A; Jandrot-Perrus, M; Pawlowski, M; Roger, S; Rosa, JP | 1 |
| Slegers, H; Van Kolen, K | 1 |
| Graff, J; Harder, S; Klinkhardt, U | 1 |
| Ishisaki, A; Kitajima, Y; Kozawa, O; Matsuno, H; Tokuda, H; Zhou, Y | 1 |
| Boehm, S; Dorostkar, MM; Edelbauer, H; Lechner, SG; Mayer, M; Pankevych, H | 1 |
| Feijge, MA; Giesen, PL; Heemskerk, JW; Jerling, JC; Kloots, W; Kuijpers, MJ; Nieuwenhuys, CM; oude Egbrink, MG | 1 |
| Aleil, B; Cazenave, JP; Gachet, C; Heitz, A; Ravanat, C; Rochoux, G | 1 |
| Heptinstall, S; May, JA; Storey, RF | 1 |
| Boeynaems, JM; Herbert, JM; Savi, P; van Giezen, H | 1 |
| Behan, MW; Fox, SC; Heptinstall, S; Storey, RF | 1 |
| Humphries, RG; van Giezen, JJ | 1 |
| Fälker, K; Lange, D; Presek, P | 1 |
| Graff, J; Harder, S | 1 |
| Gerevich, Z; Illes, P; Müller, C | 1 |
| Barbaras, R; Boeynaems, JM; Champagne, E; Collet, X; Gachet, C; Jacquet, S; Malaval, C; Martinez, LO; Nauze, M; Perez, C; Perret, B; Rolland, C; Sak, K; Tercé, F | 1 |
| Buckland, RJ; Holgate, CE; Judge, HM; Storey, RF | 1 |
| Hardy, AR; Hill, DJ; Poole, AW | 1 |
| Johansson, K; Lindahl, TL; Nylander, S; Van Giezen, JJ | 1 |
| Goto, S; Ishida, H; Ruggeri, ZM; Tamura, N | 1 |
| Garcia, A; Kim, S; Kunapuli, SP; Prabhakar, J; Shankar, H | 1 |
| Becker, RC; Bittl, JA; Clegg, J; Emanuelsson, H; Gilchrist, IC; Greenbaum, AB; Grines, CL; Grogan, DR; Harrington, RA; Kereiakes, DJ; Stankowski, JE; Weaver, WD | 1 |
| Cudd, LA; Fugate, SE | 1 |
| Kamae, T; Kanakura, Y; Kashiwagi, H; Kato, H; Kurata, Y; Shiraga, M; Tadokoro, S; Tomiyama, Y | 1 |
| Harrison, P; Pidcock, M | 1 |
| Christensen, K; Elgue, G; Emanuelsson, H; Larsson, A; Larsson, R | 1 |
| Gurbel, PA; Tantry, US | 1 |
| Cerletti, C; de Gaetano, G; Pampuch, A | 1 |
| Cattaneo, M; Lecchi, A | 1 |
| Cattaneo, M | 3 |
| Brandl, R; Deckmyn, H; Penz, SM; Reininger, AJ; Siess, W; Toth, O | 1 |
| Rich, JD; Wiviott, SD | 1 |
| Akers, WS; Charnigo, R; Ferraris, S; Oestreich, JH; Oh, JJ; Steinhubl, SR | 1 |
| Holmes, CE; Madsen, NJ; Schneider, DJ; Serrano, FA; Sobel, BE | 1 |
| Borzak, S; Emanuelsson, H; Gibson, CM; Greenbaum, AB; Le May, MR; Lu, M; Ohman, EM; Stankowski, JE; Stebbins, AL; Weaver, WD | 1 |
| Fox, SC; Heptinstall, S; White, AE; Wilcox, RG; Xavier, RG | 1 |
| Angiolillo, DJ | 1 |
| Inoue, K; Irino, Y; Kohsaka, S; Nakamura, Y; Ohsawa, K | 1 |
| Buckland, RJ; Jakubowski, JA; Judge, HM; Storey, RF; Sugidachi, A | 1 |
| Dovlatova, NL; Fox, SC; Glenn, JR; Heptinstall, S; Manolopoulos, P; May, JA; Ralevic, V; Tang, SW; Thomas, NR | 1 |
| Inoue, K; Kohsaka, S; Miyata, H; Tozaki-Saitoh, H; Tsuda, M; Ueda, K | 1 |
| Dovlatova, NL; Heptinstall, S; Jakubowski, JA; Sugidachi, A | 1 |
| Dovlatova, N; Heptinstall, S; Johnson, A | 1 |
| Abbracchio, MP; Fantucci, P; Parravicini, C; Ranghino, G | 1 |
| Barker, CM; Price, MJ | 1 |
| Angiolillo, DJ; Capranzano, P | 1 |
| Angiolillo, DJ; Guzman, LA | 1 |
| Dovlatova, N; Fox, SC; Heptinstall, S; Johnson, AJ; Latif, ML; Manolopoulos, P; Ralevic, V; White, AE; Wijeyeratne, YD | 1 |
| Di Pasquale, F; Hoffmann, K; Sixel, U; von Kügelgen, I | 1 |
| Barbaras, R; Champagne, E; Collet, X; Laffargue, M; Malaval, C; Martinez, LO; Peres, C; Perret, B; Rolland, C; Tercé, F | 1 |
| Eikelboom, JW; Hirsh, J; Raju, NC | 1 |
| Béres, BJ; Kerecsen, G; Kiss, RG; László, A; Masszi, T; Préda, I; Tóth-Zsámboki, E; Vargová, K | 1 |
| Abu-Fadel, M; Norgard, NB | 1 |
| Dovlatova, N; Espinosa, DI; Fox, SC; Glenn, JR; Gurney, M; Hartman, D; Heptinstall, S; Hermann, D; Johnson, A; Magnusson, O; Manolopoulos, P; May, JA; Stefansson, K; White, AE | 1 |
| Akram, F; Akram, S; Postuła, M | 1 |
| Angiolillo, DJ; Bhatt, DL; Gurbel, PA; Jennings, LK | 1 |
| Schneider, DJ; Sobel, BE | 1 |
| Bhavaraju, K; Bynagari, YS; Kim, S; Kunapuli, SP; Nagy, B; Tuluc, F; Vijayan, KV | 1 |
| Huang, JS; Khasawneh, FT; Lam, SC; Le Breton, GC; Mir, F; Srinivasan, S | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Fox, SC; Heptinstall, S; May, JA; Neubert, U; Shah, A | 1 |
| Blade, CL; Das, K; Das, P; Doby, JB; Mukherjee, D; Oliphant, CS | 1 |
| Norgard, NB | 1 |
| Akers, WS; Ferraris, S; Oestreich, JH; Oh, JJ; Steinhubl, SR; Wethington, M | 1 |
| Angiolillo, DJ; Ferreiro, JL; Ueno, M | 2 |
| Franchini, M; Mannucci, PM | 1 |
| Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD | 1 |
| Arneja, J; Bhatt, DL; Chew, DP; Cura, F; Gibson, CM; Goodman, SG; Harrington, RA; Jafar, MZ; Kleiman, NS; Lincoff, AM; Mahaffey, KW; Manoukian, SV; Manukov, I; McNulty, S; Montalescot, G; Pollack, CV; Skerjanec, S; Stone, GW; Tousek, F; White, HD; Widimsky, P | 1 |
| Kastrati, A; Ndrepepa, G | 1 |
| Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J | 1 |
| del Río, A; Heras, M | 1 |
| Jilma, B; Krumphuber, J; Siller-Matula, JM | 1 |
| Brunner, KP; Kobsar, AL; Koessler, J; Rajkovic, MS; Steigerwald, U; Walter, U | 1 |
| Bushell, TJ; Kennedy, C; Parmar, M; Shrestha, SS | 1 |
| Bouman, HJ; de Maat, MP; Hackeng, CM; Kruit, A; Leebeek, FW; Rudez, G; Ruven, HJ; Ten Berg, JM; van Werkum, JW | 1 |
| Cattaneo, M; Podda, GM | 1 |
| Faxon, DP | 1 |
| Ruparelia, N; Spyrou, N | 1 |
| Favaloro, EJ; Franchini, M; Lippi, G | 1 |
| Barrabés, JA; Figueras, J; Garcia-Dorado, D; Hernando, V; Inserte, J; Mirabet, M; Quiroga, A | 1 |
| Caicedo, J; Dong, A; Gairola, CG; Han, SG; Mueller, P; Saha, S; Smyth, SS | 1 |
| Lee, KL | 1 |
| Ashby, B; Jin, J; Kunapuli, SP; Mao, Y; Zhang, L | 1 |
| Inoue, K; Kiyama, H; Maeda, M; Tozaki-Saitoh, H; Tsuda, M | 1 |
| Chintala, M; Kurowski, S; Li, Q; Strony, J; Yang, B | 1 |
| Ding, Z; Du, H; Guo, Y; Hu, L; Jin, J; Kunapuli, SP; Liu, J; Niu, H; Zhang, J; Zhang, S; Zhang, X; Zhang, Y | 1 |
| Ben Addi, A; Boeynaems, JM; Briand, F; Collet, X; Combes, G; Fabre, AC; Huby, T; Lichtenstein, L; Malaval, C; Martinez, LO; Nijstad, N; Perret, B; Pons, V; Robaye, B; Serhan, N; Tietge, UJ; Verdier, C | 1 |
| Bauersachs, J; Flierl, U; Kobsar, AL; Koessler, J; Pfoertsch, S; Rajkovic, MS; Rechner, AR; Schafer, A; Steigerwald, U; Walter, U | 1 |
| Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; Nylander, S; van Giezen, H; White, AE | 1 |
| Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; White, AE | 1 |
| Frey, N; Ivandic, B | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| Akers, WS; Ferraris, SP; Oestreich, JH; Steinhubl, SR | 1 |
| Storey, RF | 2 |
| Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J | 1 |
| Chiżyński, K; Golański, J; Kuliczkowski, W; Rychlik, B; Watała, C | 1 |
| Cattaneo, GJ; Cattaneo, M; Podda, GM | 1 |
| Dovlatova, N; Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; White, AE | 1 |
| Boehm, S; Klinger, F; Schicker, K; Yousuf, A | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Böhm, M; Schirmer, SH | 1 |
| Caglayan, E; Er, F; Erdmann, E; Gassanov, N | 1 |
| Ding, Z; Du, H; Fan, Z; Gross, PL; Hu, L; Kunapuli, SP; Ni, R; Wei, X; Ye, J; Yin, K; Zhang, S; Zhang, X; Zhang, Y | 1 |
| Berndt, M; Canney, A; Conlon, N; Crowley, D; Ducrée, J; Dunne, E; Egan, K; Ffrench, B; Finn, S; Gallagher, M; Keegan, H; Kenny, D; Laios, A; Martin, C; McEneaney, V; McEvoy, L; Norris, L; O'Leary, J; O'Toole, S; Sheils, O; Smith, L; Smyth, P; Spillane, C; Stordal, B | 1 |
| Angiolillo, DJ; Brtko, M; Cannon, L; Chandna, H; Dyke, C; Firstenberg, MS; Hutyra, M; Liu, T; Manoukian, SV; Montalescot, G; Prats, J; Price, MJ; Ramaiah, C; Topol, EJ; Tummala, PE; Voeltz, MD; Welsby, IJ | 1 |
| Bhatt, DL; Chew, DP; Dauerman, HL; Gibson, CM; Gruberg, L; Harrington, RA; Mahaffey, KW; Stone, GW; White, HD | 1 |
| Contractor, H; Ruparelia, N | 1 |
| Balkau, B; Greiner, TO; Krajewski, S; Kurz, J; Neumann, B; Peter, K; Stolz, A; Straub, A; Unertl, K; Wendel, HP | 1 |
| Dibattiste, PM; Ringwala, SM; Schneider, DJ | 1 |
| Lavi, R; Lavi, S | 1 |
| Angiolillo, DJ; Becker, RC; Bhatt, DL; French, WJ; Harrington, RA; Huber, K; Liu, T; Prats, J; Price, MJ; Saucedo, JF; Schneider, DJ; Shaburishvili, T | 1 |
| Bhatt, DL; Dietrich, M; Gallup, D; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; Price, MJ; Skerjanec, S; Steg, GW; Stone, GW; Todd, M; White, HD | 1 |
| Barn, K; Steinhubl, SR | 1 |
| Ding, Z; Hu, L; Kunapuli, SP; Li, Y; Ye, J; Zhang, S; Zhang, SH; Zhang, Y | 1 |
| Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J | 1 |
| Bernlochner, I; Sibbing, D | 1 |
| Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Guzman, LA; Rollini, F; Tello-Montoliu, A; Tomasello, SD; Ueno, M | 1 |
| Cohen, MV; Cui, L; Downey, JM; Kambayashi, J; Liu, Y; Tandon, N; Yang, X; Yang, XM | 2 |
| Gartner, TK; Li, Z; Morris, AJ; Ren, H; Smyth, SS; Sunkara, M; Xiang, B; Zhang, G | 1 |
| Cabou, C; Laffargue, M; Lichtenstein, L; Malet, N; Martinez, LO; Perret, B; Serhan, N; Verdier, C | 1 |
| Brass, LF; Cermignano, SL; Diamond, SL; Stalker, TJ; Traxler, EA; Voronov, R; Wannemacher, KM; Wu, J | 1 |
| Beck, F; Buhs, S; Geiger, J; Gerull, H; Nollau, P; Schweigel, H; Sickmann, A; Walter, U | 1 |
| Roubille, F; Tardif, JC | 1 |
| Bhatt, DL; Gibson, CM; Harrington, RA; Leonardi, S; Mahaffey, KW; Neely, ML; Stone, GW; Tricoci, P; Truffa, AA; White, HD; Wilson, M | 1 |
| Angiolillo, DJ; Bhatt, DL; Bramucci, E; Gallup, D; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; McLaurin, BT; Prats, J; Price, MJ; Radke, PW; Skerjanec, S; Spriggs, D; Steg, PG; Stone, GW; Tauth, J; Todd, M; Tousek, F; White, HD; Widimský, P | 1 |
| Hillis, LD; Lange, RA | 1 |
| Mills, NL; Newby, DE; Shah, AS | 1 |
| Angiolillo, DJ; Brtko, M; Cannon, LA; Chandna, H; Chronos, N; Dietrich, M; Dyke, CM; Firstenberg, MS; Holmes, DR; Hutyra, M; Liu, T; Manoukian, SV; Montalescot, G; Prats, J; Price, M; Ramaiahm, C; Todd, M; Topo, EJ; Tummala, P; Voeltz, M; Welsby, I | 1 |
| Mitka, M | 1 |
| Augoustides, JG; Lane, B; Patel, PA | 1 |
| Alhammouri, A; Cohen, MV; Cui, L; Downey, JM; Yang, XM | 1 |
| Giugliano, RP; Shimada, YJ | 1 |
| Manoukian, SV; Voeltz, MD | 1 |
| Alves, CM; Caixeta, AM; Carvalho, AC; Carvalho, L; Chan, M; Falcão, FJ | 1 |
| Bellibas, SE; Green, CL; Krucoff, MW; Lambe, L; Prats, J; Whellan, DJ; Wijngaard, P | 1 |
| Bhatt, DL; Curzen, N; Gurbel, PA; Myat, A; Redwood, SR | 1 |
| Aylward, PE; Sinhal, AR | 1 |
| Mehta, SR | 1 |
| Bhatt, DL; Day, JR; French, WJ; Gibson, CM; Gogia, HS; Gruberg, L; Hamm, CW; Harrington, RA; Iwaoka, RS; Leonardi, S; Liu, T; Mahaffey, KW; Skerjanec, S; Steg, PG; Stone, GW; Stuckey, TD; White, HD | 1 |
| Chatterjee, S; Mushiyev, S; Nairooz, R; Pekler, G; Sardar, P; Visco, F | 1 |
| Aradi, D; Kim, MH; Serebruany, VL; Sibbing, D | 1 |
| Aryal Pandit, A; Aryal, MR; Hakim, FA; Jalota, L; Lee, HR; Mookadam, F; Pandit, A; Tleyjeh, IM | 1 |
| Limbruno, U; Musumeci, G | 1 |
| Angiolillo, DJ; Cho, JR; Franchi, F; Muñiz-Lozano, A; Rollini, F | 1 |
| Kassassir, H; Siewiera, K; Sychowski, R; Watała, C | 1 |
| Angiolillo, DJ; Bhatt, DL; Brener, SJ; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; LaSalle, L; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Skerjanec, S; Steg, PG; Stone, GW; Todd, M; White, HD | 1 |
| DiNicolantonio, JJ; Serebruany, VL; Sibbing, D | 1 |
| DiNicolantonio, JJ; Fortmann, SD; Pokov, AN; Serebruany, VL | 1 |
| Verheugt, FW | 1 |
| Andruszkiewicz, A; Fabiszak, T; Gurbel, PA; Jeong, YH; Kozinski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM; Tantry, U | 1 |
| Price, MJ; Walsh, JA | 1 |
| Jover, E; Tello-Montoliu, A; Valdés, M | 1 |
| Akers, WS; Ferraris, SP; Loftin, CD; Oestreich, JH; Steinhubl, SR | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Sabouret, P; Taiel-Sartral, M | 1 |
| Angiolillo, DJ; Bass, TA; Cho, JR; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM | 1 |
| Agarwal, Z; Gogo, P; Keating, FK; Schneider, DJ; Seecheran, N | 1 |
| Caldeira, D; Ferreira, JJ; Pinto, FJ | 1 |
| Dobesh, PP; Oestreich, JH | 1 |
| Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P | 1 |
| Leonardi, S; Marino, M; Rizzotti, D | 1 |
| Abbracchio, MP; Castiglioni, L; Colazzo, F; Cosentino, S; Nobili, E; Pesce, M; Rosa, P; Sironi, L; Tremoli, E | 1 |
| Bonadei, I; D'Aloia, A; Metra, M; Raddino, R; Sciatti, E; Vizzardi, E | 1 |
| Bune, LT; Kylhammar, D; Rådegran, G | 1 |
| Gogo, P; Keating, FK; Raza, SS; Schneider, DJ; Seecheran, N | 1 |
| Phan, YL; Spinler, SA; Waite, LH | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Alexeyev, M; Cohen, MV; Cui, L; Downey, JM; Gillespie, MN; Kuck, J; Ruchko, MV; White, J; Wilson, GL; Yang, XM | 1 |
| Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M | 1 |
| Guasti, L; Riva, N; Squizzato, A; Tamborini Permunian, E | 1 |
| Baker, NC; Lhermusier, T; Waksman, R | 1 |
| Grenegård, M; Lindström, EG; Öllinger, K; Ramström, S; Södergren, AL; Svensson Holm, AC | 1 |
| Angiolillo, DJ; Bhatt, DL; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Bell, RM; Cohen, MV; Downey, JM; Kunuthur, SP; Sivaraman, V; Yellon, DM | 1 |
| Traynor, K | 1 |
| Keating, GM | 1 |
| Buckland, RJ; Jakubowski, JA; Judge, HM; Storey, RF | 1 |
| Bye, AP; Fry, MJ; Gibbins, JM; Stainer, AR; Unsworth, AJ; Vaiyapuri, S | 1 |
| Agarwal, Z; Gogo, P; Schneider, DJ; Seecheran, N | 1 |
| Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Schneider, DJ | 1 |
| Angiolillo, DJ; Franchi, F; Park, Y; Rollini, F | 1 |
| Frelinger, AL; Gremmel, T; Michelson, AD; Przyklenk, K; Undyala, VV; Wider, J; Wright, GE; Yanachkov, IB; Yanachkova, MI | 1 |
| Blazejczyk, A; Kalchenko, V; Przygodzki, T; Talar, M; Watala, C | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; O'Donoghue, ML; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Bell, RM; Cohen, MV; Downey, JM; White, J; Yang, XM; Yellon, DM | 1 |
| Bhatt, DL; Qamar, A | 2 |
| Bolek, T; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Jatene, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Basabe-Desmonts, L; Gilmartin, N; Jose, B; Kenny, D; Kent, NJ; McCluskey, P; Ricco, AJ; Somers, M | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Abbracchio, MP; Coppolino, G; Daniele, S; Eberini, I; Gianazza, E; Martini, C; Palazzolo, L; Parravicini, C; Primi, R; Trincavelli, ML; Zaratin, P | 1 |
| Cahoon, WD; Francis, KE; Lowe, DK; Magee, LC; Oswalt, AK | 1 |
| Cinalli, AR; Fernández, V; Guarracino, JF; Losavio, AS; Roquel, LI | 1 |
| Burris, RJ; Seto, AH; Tyler, JM | 1 |
| Drebes, A; Klonaris, C; Liakakos, T; Matheiken, S; Patelis, N | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD | 2 |
| Sinha, A; Storey, RF | 1 |
| Bhatt, DL; Cavender, MA; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Abnousi, F; Bhatt, DL; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Mangum, S; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; Todd, M; White, HD; Wilson, M | 1 |
| Hussar, DA | 1 |
| Alboji, A; Droppa, M; Gawaz, M; Geisler, T; Jeong, YH; Müller, KAL; Rath, D; Spahn, P; Straub, A; Takhgiriev, K | 1 |
| Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Kerneis, M; Montalescot, G; Silvain, J | 1 |
| Adamska, U; Adamski, P; Koziński, M; Kubica, J; Ostrowska, M | 1 |
| Bhatt, DL; Fuster, V; Gersh, BJ; Lennon, RJ; Narula, J; Rihal, CS; Singh, M; Stone, GW | 1 |
| Ferreiro, JL; Marcano, AL | 1 |
| Andell, P; Erlinge, D; Götberg, M; James, S; Koul, S; Mohammad, MA; Scherstén, F | 1 |
| Price, MJ | 1 |
| Bhatt, DL; Deliargyris, EN; Elkin, S; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD | 1 |
| Bhatt, DL; Croce, KJ; Faxon, DP; Leopold, JA; Mauri, L; Qamar, A; Shah, PB; Singh, A; Sobieszczyk, P; Szumita, PM; Vaduganathan, M; Venkateswaran, RV | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD | 1 |
| Brar, SS | 1 |
| Lipinski, MJ; Torguson, R; Waksman, R; Westman, PC | 1 |
| Frelinger, AL; Gerrits, AJ; Jakubowski, JA; Michelson, AD; Sugidachi, A | 1 |
| Amann, M; Bömicke, T; Ferenc, M; Hauschke, D; Hochholzer, W; Kleiner, P; Löffelhardt, N; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM; Younas, I | 1 |
| Lambertucci, C; Volpini, R; Zhang, W; Zhou, S; Zhuo, T | 1 |
| Gillard, M; Gomeza, J; Hennen, S; Kostenis, E; Merten, N; Mohr, K; Peters, L; Preis, P; Schmitt, NK; Schrage, R; Schröder, R; Simon, K; Vermeiren, C | 1 |
| Bekő, K; Botz, B; Dénes, Á; Gölöncsér, F; Helyes, Z; Horváth, G; Környei, Z; Koványi, B; Müller, CE; Sperlágh, B | 1 |
| Bhatt, DL; Day, JRS; Gibson, CM; Hamm, CW; Mahaffey, KW; Parker, WA; Prats, J; Price, MJ; Steg, PG; Stone, GW; Storey, RF; White, HD | 1 |
| Abnousi, F; Bhatt, DL; Deliargyris, EN; Desai, M; Ding, VY; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Sundaram, V; White, HD; Yang, L; Yong, CM | 1 |
| Chang, L; Ding, Z; Hu, L; Kunapuli, SP; Luo, X; Qi, Z; Wang, Y; Yan, H; Yan, Y; Ye, H; Zhai, L; Zhang, S; Zhang, Y | 1 |
| Angiolillo, DJ; Bass, TA; Been, L; Cho, JR; Faz, G; Franchi, F; Kureti, M; Park, Y; Rollini, F; Thano, E | 1 |
| Nei, SD; Seelhammer, TG; Skiba, J; Wittwer, ED | 1 |
| Bhatt, DL; Borst, O; Droppa, M; Gawaz, M; Geisler, T; Müller, K; Rath, D | 1 |
| Badreldin, HA; Bhatt, DL; Faxon, DP; Qamar, A; Vaduganathan, M | 2 |
| Bhatt, DL; Deliargyris, EN; Eisen, A; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Heramvand, N; Jung, C; Kelm, M; Kollmann, M; Masyuk, M; Muessig, JM; Nia, AM; Polzin, A | 1 |
| Moliterno, DJ | 1 |
| Lozano, I; Rondan, J; Segovia, E; Vegas, JM | 1 |
| Alexopoulos, D; Lekakis, J; Pappas, C; Sfantou, D | 1 |
| Droppa, M; Geisler, T | 1 |
| Ferenc, M; Hochholzer, W; Löffelhardt, N; Mashayekhi, K; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM | 1 |
| Angiolillo, DJ; Bhatt, DL; Deliargyris, EN; Gibson, CM; Groves, EM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Curzen, N; Mamas, MA | 1 |
| Gernhofer, YK; Khoche, S; Pretorius, V; Ross, M | 1 |
| Amin, AP; Bhatt, DL; Fan, W; Généreux, P; Gibson, CM; Harrington, RA; Kirtane, AJ; Pinto, DS; Stone, GW; Tamez, H; White, HD; Yeh, RW | 1 |
| Maus, T; Pretorius, V; Ross, M; Seider, S | 1 |
| DeVore, AD; Milano, CA; Patel, CB; Washam, JB; Welsby, IJ; Yerokun, B | 1 |
| Cetran, L; Coste, P; Fiore, M; Gerbaud, E; Marchand, H; Seguy, B | 1 |
| Lu, YB; Tian, YX; Wang, Q; Wu, M; Wu, ZX; Zhan, TW; Zhang, WP | 1 |
| Feih, JT; Garner Rinka, JR; Laehn, SJ; Saltzberg, MT | 1 |
| Bowman, S; Gass, J; Weeks, P | 1 |
| Calnan, MW; Crawford, AN | 1 |
| Bhatt, DL; Deliargyris, EN; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Alexopoulos, D; Didagelos, M; Iliodromitis, E; Karvounis, H; Kikas, P; Pappas, C; Sfantou, D; Tziakas, D; Xanthopoulou, I; Ziakas, A | 1 |
| Bryant, JA; Bulluck, H; Chai, P; Chan, MHH; Chan, MY; Chawla, A; Chua, TS; Chung, YC; Fei, G; Hausenloy, DJ; Ho, AFW; Ho, HH; Hock, MOE; Hoe, AJ; Imran, SS; Lee, CH; Liew, BW; Lim, SH; Paradies, V; Roe, MT; Tan, JW; Teo, L; Watson, T; Wong, AS; Wong, E; Wong, PE; Yun, PLZ | 1 |
| Boncler, M; Polak, D; Rozalski, M; Watala, C; Wolska, N; Wzorek, J | 1 |
| Farag, M; Gorog, DA; Gue, YX; Spinthakis, N; Srinivasan, M; Wellsted, DM | 1 |
| Aghaebrahim, A; Agnoletto, GJ; Aguilar-Salinas, P; Brasiliense, LBC; Gonsales, D; Granja, MF; Hanel, RA; Santos, R; Sauvageau, E | 1 |
| Abtan, J; Bhatt, DL; Deliargyris, EN; Ducrocq, G; Elkin, S; Gibson, CM; Hamm, C; Harrington, RA; Mahaffey, KW; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA | 1 |
| Agarwal, M; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Kaufman, M; Nawaz, A; Pineda, AM; Rivas, A; Rollini, F; Shaikh, Z; Silva, G; Smairat, R; Soffer, D; Suryadevara, S; Wali, M; Zenni, MM | 1 |
| Boyle, AJ; Danelich, IM; Entwistle, JW; Kabadi, RA; Marhefka, GD; Qureshi, AM; Reeves, G | 1 |
| Hollis, IB; Newsome, AS; Van Tuyl, JS | 1 |
| Desai, R; Doshi, R; Jain, A; Kansara, T; Majmundar, M; Mithawala, P; Shah, P | 1 |
| Banks, DA; Girgis, AM; Golts, E; Humber, D | 1 |
| Erlinge, D; Grimfjärd, P; James, S; Lagerqvist, B; Varenhorst, C | 1 |
| Beyene, S; Brathwaite, E; Buchanan, K; Dan, K; Dheendsa, A; Gajanana, D; Garcia-Garcia, HM; Hideo-Kajita, A; Iantorno, M; Kolm, P; Meirovich, Y; Melaku, G; Ozaki, Y; Rogers, T; Torguson, R; Waksman, R | 1 |
| Bhatt, DL; de Waha-Thiele, S; Desch, S; Droppa, M; Fuernau, G; Gawaz, M; Geisler, T; Hack, L; Jaffer, FA; Ouarrak, T; Qamar, A; Rath, D; Roberts, RJ; Schneider, S; Singh, A; Szumita, PM; Thiele, H; Vaduganathan, M; Venkateswaran, RV; Zeymer, U | 1 |
| Brook, RP; Cruz, D; Hu, TY; Kamdar, NV; Macyszyn, L; Moreland, NC; Nagasawa, DT; Park, S; Peeters, SM; Press, MC; Sun, J | 1 |
| Abtan, J; Bhatt, DL; Deliargyris, EN; Ducrocq, G; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Capodanno, D; Capranzano, P | 1 |
| Erlinge, D | 1 |
| Syed, S; Wąsowicz, M | 1 |
| Anireddy, JS; Chidambaram Subramanian, V; Guvvala, V | 1 |
| Dagois, S; De Mesmay, M; Devys, JM; Dupont, C; Godier, A; Mazighi, M; Mesnil, M; Thion, LA | 1 |
| Leonardi, S; Meani, P; Morici, N; Nava, S; Oliva, F; Oreglia, J; Ranucci, M; Rossini, R; Sacco, A; Viola, G | 1 |
| Bernardo, NL; Chen, Y; Waksman, R | 1 |
| Chen, Y; Khalid, N; Rogers, T; Shlofmitz, E; Waksman, R | 1 |
| Armesilla, AL; Berry, C; Cotton, JM; Ford, TJ; Hothi, SS; Khan, N; Khogali, SS; Martins, J; McAlindon, EJ; Munir, S; Murray, HM; Thomas, MR; Townend, JN; Ubaid, S; Wrigley, B | 1 |
| Andrews, RK; Clark, JC; Gardiner, EE; Hill, SJ; Kavanagh, DM; Pike, JA; Poulter, NS; Watson, S; Watson, SP | 1 |
| Bhatt, DL; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Mangum, S; Olivier, CB; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilson, MD | 1 |
| Abdennour, L; Bernard, R; Carpentier, A; Clarençon, F; Degos, V; Drir, M; Godier, A; Lenck, S; Mathout, J; Premat, K; Shotar, E; Sourour, N; Taylor, G | 1 |
| Erdoes, G; Koster, A; Reid, C | 1 |
| Alberio, L; Iafrate, M; Kirsch, M; Marcucci, C; Pantet, O; Pitta-Gros, B; Scala, E | 1 |
| Henderson, R; Tanaka, KA; Williams, B | 1 |
| Alexopoulos, D; Lianos, I; Mpahara, A; Varlamos, C | 1 |
| Aseni, P; Cereda, AF; Chiara, O; Morici, N | 1 |
| Ciolek, AM; Eisenberger, AB; Garan, AR; Jennings, DL; Ma, K | 1 |
| Banks, DA; Girgis, AM | 1 |
| Di Tano, G; Galeazzi, G; Loffi, M; Passamonti, E; Pedroni, P | 1 |
| Arai, N; Enomoto, Y; Ishida, H; Kitano, K; Komiyama, Y; Omori, Y; Sakayori, T; Uematsu, K; Watanabe, Y | 1 |
| Baillie, JK; Chan, MV; Dru, RC; Graham, CJ; Lee, EW; Paterson, GG; Thompson, AAR; Torpey, GS; Walmsley, SR; Warner, TD; Willson, JA; Young, JM | 1 |
| Boncler, M; Gapinska, M; Polak, D; Przygodzki, T; Rozalski, M; Watala, C; Wolska, N; Wzorek, J | 1 |
| Ahmed, S; Choxi, R; Jovin, IS; Pillai, A | 1 |
| Absi, M; Beasley, G; Boston, U; Sainathan, S | 1 |
| Bozzi, S; Cattaneo, M; Mencarini, T; Podda, G; Redaelli, A; Scavone, M | 1 |
| Garcia-Garcia, HM; Jeremias, A; Melaku, GD; Sacher, H; Shlofmitz, E; Shlofmitz, R; Thomas, SV; Torguson, R; Waksman, R | 1 |
| Feng, KY; Mahaffey, KW | 1 |
| Leonardi, S; Marianeschi, SM; Morici, N; Pedrazzini, G; Sirico, D; Soriano, F; Vignati, G | 1 |
| Avvedimento, M; Billinger, M; Campo, G; Cirillo, P; Esposito, G; Gargiulo, G; Gragnano, F; Heg, D; Hunziker, L; Manavifar, N; Minuz, P; Nagler, M; Piccolo, R; Tebaldi, M; Valgimigli, M; Wahl, A; Windecker, S | 1 |
| Alberio, L; Gerschheimer, C; Gomez, FJ; Marcucci, C; Scala, E | 1 |
| Dong, L; Lu, Y; Wang, Q; Wei, T; Wu, M; Wu, Z; Yan, Q; Zhan, T; Zhang, W | 1 |
| Finniss, M; Helton, T; Khalid, M; Khan, AA; Murtaza, G | 1 |
| Auger, WR; Forfia, PR; Mishra, S; Morewood, GH; Salamanca-Padilla, YY; Ta, J; Toyoda, Y; Vaidya, A | 1 |
| Alamowitch, S; Clarençon, F; Degos, V; Drir, M; Elhorany, M; Frasca Polara, G; Godier, A; Lenck, S; Mahtout, J; Premat, K; Samson, Y; Shotar, E; Sourour, NA | 1 |
| Brassart-Pasco, S; Djerada, Z; Feliu, C; Millart, H; Nguyen, P; Oszust, F; Peyret, H; Poitevin, G | 1 |
| Dabus, G; Linfante, I; Ravipati, K; Reyes, D; Starosciak, AK | 1 |
| Canonico, ME; Parodi, G; Saba, PS; Siciliano, R; Talanas, G | 1 |
| Boulos, AS; Dalfino, JC; Entezami, P; Field, NC; Holden, DN; Nourollahzadeh, E; Paul, AR; Yamamoto, J | 1 |
| Geube, M; Sale, S | 1 |
| Buono, A; De Blasio, G; Ielasi, A; Loffi, M; Tespili, M | 1 |
| Christensen, MG; Hamilton, ADM; Hvas, AM; Johnsen, N; Praetorius, H; Rubak, P; Skals, M | 1 |
| Ata, O; Inci, TG; Kocer, S; Mutlu, O; Sariyer, E; Turgut-Balik, D; Ugurel, E; Ugurel, OM | 1 |
| Barchetti, G; Boccardi, E; Cervo, A; Ferrari, F; Pero, G; Piano, M; Quilici, L | 1 |
| Alexander, J; Allada, V; Allen, B; Bacha, E; Diacovo, T; Diamond, S; Kreutzer, J; Krishnamurthy, G; Morell, V; Price, M; Schmidhofer, J; Vargas, D; Vincent, J; Yeh, J; Yu, X; Zhou, H | 1 |
| Aghaebrahim, A; Aguilar-Salinas, P; Clarençon, F; Cortez, GM; Dabus, G; Elhorany, M; Grigoryan, M; Hanel, RA; Linfante, I; Mirza, S; Monteiro, A; Murtaza, Y; Sauvageau, E; Sourour, N | 1 |
| Abdel-Latif, A; Abo-Aly, M; Chelvarajan, L; El-Helw, M; George, B; Shokri, E; Smyth, SS; Ziada, K | 1 |
| Aknouche, S; Allard, J; Blanc, R; Ciccio, G; Delvoye, F; Desilles, JP; Escalard, S; Hebert, S; Labreuche, J; Maertens de Noordhout, A; Maier, B; Mazighi, M; Obadia, M; Olivot, JM; Piotin, M; Redjem, H; Sabben, C; Smajda, S; Thion, LA | 1 |
| Ishigaku, Y; Itabashi, R; Kamada, A; Maeda, T; Narumi, S; Natori, T; Oi, K; Oura, K; Shimizu, M; Terayama, Y; Tsuda, K; Yoshida, M | 1 |
| Arora, L; Hayden, AM; Hobbs, RA; Sharafuddin, MJ | 1 |
| Altshuler, D; Arnouk, S; Katz, A; Lewis, TC; Merchan, C; Papadopoulos, J; Smith, DE; Toy, B | 1 |
| Agostini, C; Bernardo, P; Caniato, F; Cappelli, F; Di Filippo, C; Di Mario, C; Mattesini, A; Meucci, F; Sori, A; Stolcova, M | 1 |
| Angiolillo, DJ; Bhatt, DL; Stone, GW | 1 |
| Gargiulo, G; Nagler, M; Valgimigli, M | 1 |
| Boulos, AS; Dalfino, JC; Entezami, P; Field, NC; Holden, DN; Paul, AR | 1 |
| Bonda, TA; Karolczak, K; Kramkowski, K; Polak, D; Przygodzki, T; Talar, M; Watala, C; Wojkowska, DW; Wolska, N | 1 |
| Boulos, A; Dalfino, J; Entezami, P; Field, N; Holden, D; Paul, AR | 1 |
| Ben-Dor, I; Bernardo, NL; Case, BC; Chezar-Azerrad, C; Forrestal, BJ; Garcia-Garcia, HM; Hashim, H; Medranda, GA; Satler, LF; Shea, C; Waksman, R; Yerasi, C; Zhang, C | 1 |
| Fan, D; Li, Q; Ma, LJ; Mao, YH; Tian, Z; Wan, JB; Ya, F; Yang, Y; Zhao, M; Zhao, Y; Zuo, X | 1 |
| Biondi-Zoccai, G; Carulli, E; Cirillo, P; D'Alessandro, P; Ercolano, V; Esposito, G; Favale, S; Forleo, C; Giordano, A; Larosa, C; Moscarelli, M; Nestola, PL; Palmiotto, AI; Pepe, M | 1 |
| Bourcier, R; Chalumeau, V; Clarençon, F; Consoli, A; Darcourt, J; Dargazanli, C; Delvoye, F; Desilles, JP; Elhorany, M; Finitsis, S; Gariel, F; Gory, B; Lapergue, B; Marnat, G; Mazighi, M; Richard, S; Sibon, I | 1 |
| Angiolillo, DJ; Bhatt, DL; Capodanno, D; De Luca, L; Steg, PG | 1 |
| Chen, G; Guo, D; Hang, M; Jin, Q; Kang, Q; Liu, G; Liu, R; Luo, Q; Qu, K; Xu, L | 1 |
| Boulos, AS; Bush, MC; Dalfino, JC; Entezami, P; Field, NC; Holden, DN; Paul, AR; Yamamoto, J | 1 |
| Angiolillo, DJ; Banerjee, S; Bhatt, DL; Cantrell, S; Jones, WS; Mehran, R; Nanna, MG; Ohman, EM; Rao, SV; Rymer, JA; Sullivan, AE; Wang, TY; Washam, JB | 1 |
| Berteotti, M; Carrabba, N; Ciatti, F; Gori, AM; Marchionni, N; Marcucci, R; Migliorini, A; Muraca, I; Valenti, R; Valgimigli, M | 1 |
| Angiolillo, DJ; Bass, TA; Been, L; Franchi, F; Galli, M; Ghanem, G; Pineda, AM; Rivas, A; Rollini, F; Shalhoub, A; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X | 1 |
| Acker, MA; Domenico, C; Fanaroff, AC; Horton, ER; Johnson, BV; Kolansky, DM; Nathan, AS | 1 |
| Bogoutdinova, A; Gambaryan, S; Kharazova, A; Mindukshev, I; Rukoyatkina, N; Shpakova, V | 1 |
| Bhatt, DL; Cavender, MA; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Gargiulo, G; Landi, A; Valgimigli, M | 1 |
| Angiolillo, DJ; Franchi, F; Rollini, F | 1 |
| Lindberg, SA; Lopez, CN; Mobley, CM; Saharia, A; Sheth, S; Succar, L; Victor, DW | 1 |
| Huang, SY; Li, H; Lin, KN; Zhang, K; Zhao, W | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Peterson, BE; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Arquizan, C; Bourcier, R; Bourdain, F; Caroff, J; Chalumeau, V; Clarençon, F; Consoli, A; Darcourt, J; Dargazanli, C; Delvoye, F; Denier, C; Desilles, JP; Elhorany, M; Finistis, S; Gariel, F; Gory, B; Lapergue, B; Marnat, G; Mazighi, M; Olivot, JM; Richard, S; Rosso, C; Sibon, I; Veunac, L | 1 |
| Ji, CS; Roberts, RJ; Solomon, EJ; Toyoda, AY; Yun, AN | 1 |
| Angiolillo, DJ; Bhatt, DL; Davidson-Ray, L; Dell'Anna, C; Diaz, M; Edwards, L; El-Sabae, H; Garratt, KN; Ohman, EM; Rymer, JA; Salahuddin, K; Tasissa, G; Waksman, R; Wang, TY; Washam, JB | 1 |
| Berti, S; Bolognese, L; Calabrò, P; Capranzano, P; Cernetti, C; Chirillo, F; Cirillo, P; Contarini, M; De Luca, L; Di Mario, C; Ferlini, M; Lanzilotti, V; Maffeo, D; Mauro, C; Menichelli, M; Menozzi, A; Muraglia, S; Musumeci, G; Nicolini, E; Pepe, M; Rolfo, C; Rossini, R; Scherillo, M; Talanas, G; Tarantini, G; Tomai, F; Trani, C; Versaci, F | 1 |
| Ahmad, M; Patel, N; Zaghloul, S | 1 |
| Bhatt, DL; Cavender, MA; Harrington, RA | 1 |
| Avvedimento, M; Borgia, F; Canonico, ME; Cirillo, P; Diserafino, L; Esposito, G; Franzone, A; Gargiulo, G; Manzi, L; Marenna, A; Paolillo, R; Piccolo, R; Simonetti, F; Sperandeo, L; Spinelli, A; Stabile, E; Valgimigli, M | 1 |
| Calleris, G; Cedrone, M; Ceraolo, E; Gontero, P; Rosboch, GL | 1 |
| Abdennour, L; Clarencon, F; Degos, V; Drir, M; Duranteau, O; Frère, C; Jacquens, A | 1 |
| Berry, TP; Haines, MM; Hayes, CH; Kozinn, JB; Mohamed, AM; Pluenneke, JC; Thomas, EL; Welge, JA; Zhurav, L | 1 |
| Ben-Dor, I; Bernardo, NL; Bhogal, S; Devineni, A; Garcia-Garcia, HM; Hashim, HD; Kallur, A; Merdler, I; Rogers, T; Satler, LF; Waksman, R; Wermers, JP | 1 |
90 review(s) available for adenosine monophosphate and cangrelor
| Article | Year |
|---|---|
The medicinal chemistry of the P2 receptor family.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Arteriosclerosis; Cloning, Molecular; Clopidogrel; Cystic Fibrosis; Humans; Ophthalmic Solutions; Polyphosphates; Receptors, Purinergic P2; Structure-Activity Relationship; Ticlopidine; Tissue Distribution; Uracil Nucleotides | 2001 |
Cangrelor AstraZeneca.
Topics: Adenosine Monophosphate; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Coronary Disease; Hemodynamics; Humans; Platelet Aggregation Inhibitors; Receptors, Purinergic; Structure-Activity Relationship | 2001 |
Advantages of fast-acting ADP receptor blockade in ischemic heart disease.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Drug Combinations; Humans; Myocardial Ischemia; Platelet Activation; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Thrombosis; Tissue Plasminogen Activator | 2003 |
Potential value of triple antiplatelet therapy for secondary stroke prevention.
Topics: Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Risk; Stroke; Treatment Outcome | 2003 |
P2Y receptor antagonists in thrombosis.
Topics: Adenosine Monophosphate; Animals; Clopidogrel; Humans; Mice; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Thrombosis; Ticlopidine | 2005 |
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Animals; Arterial Occlusive Diseases; Clinical Trials as Topic; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Female; Fibrinolytic Agents; Humans; Injections, Intravenous; Male; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Rabbits; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor | 2005 |
Cangrelor for treatment of coronary thrombosis.
Topics: Adenosine Monophosphate; Animals; Clinical Trials as Topic; Coronary Thrombosis; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists | 2006 |
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
New antiplatelet therapies for acute coronary syndromes.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Blood Platelets; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Treatment Outcome | 2007 |
ADP receptor antagonism: what's in the pipeline?
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2007 |
Pharmacology of emerging novel platelet inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor | 2008 |
Clinical overview of promising nonthienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Ticagrelor | 2008 |
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2008 |
Future prospects in anti-platelet therapy: a review of potential P2Y12 and thrombin receptor antagonists.
Topics: Adenosine Monophosphate; Animals; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Thrombosis | 2008 |
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Advances in antiplatelet therapy: agents in clinical development.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Signal Transduction; Thiophenes; Ticagrelor; Treatment Outcome | 2009 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Emerging P2Y12 receptor antagonists: role in coronary artery disease.
Topics: Adenosine; Adenosine Monophosphate; Animals; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor | 2010 |
Cangrelor: a novel P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Animals; Clinical Trials as Topic; Coronary Thrombosis; Drug Evaluation, Preclinical; Humans; Molecular Structure; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12 | 2009 |
New P2Y12 blockers.
Topics: Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Treatment Outcome | 2009 |
Cangrelor: a review on its mechanism of action and clinical development.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Animals; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12 | 2009 |
New antiplatelet agents: why they are needed.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Propionates; Pyridines; Thiophenes; Ticagrelor | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor | 2010 |
State of the art of new P2Y12 antagonists.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Update on the clinical development of cangrelor.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12 | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2011 |
[Myocardial infarction: Role of new antiplatelet agents].
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors | 2011 |
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Update on anti-platelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Thrombolytic Therapy; Ticagrelor | 2011 |
[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Pyridines; Receptors, Purinergic P2; Stents; Ticlopidine | 2011 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Perioperative management of antiplatelet agents in patients undergoing cardiac surgery.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Ticlopidine | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Thienopyridines and other ADP-receptor antagonists.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Progress in platelet blockers: the target is the P2Y12 receptor.
Topics: Adenosine; Adenosine Monophosphate; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor | 2013 |
Emerging antithrombotic drugs for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Fibrinolytic Agents; Humans; Lactones; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Thiophenes | 2013 |
What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?
Topics: Adenosine Monophosphate; Administration, Oral; Anticoagulants; Combined Modality Therapy; Humans; Infusions, Parenteral; Integrin beta3; Myocardial Infarction; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Thrombolytic Therapy | 2013 |
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Cause of Death; Coronary Disease; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Treatment Outcome | 2013 |
Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials.
Topics: Adenosine Monophosphate; Female; Hemorrhage; Humans; Male; Models, Biological; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; PubMed; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thrombosis | 2014 |
Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials.
Topics: Adenosine Monophosphate; Hemorrhage; Humans; Infusions, Intravenous; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Adenosine Monophosphate; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine | 2014 |
Cangrelor: a review on pharmacology and clinical trial development.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Animals; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists | 2013 |
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
Topics: Acute Lung Injury; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Sulfonamides; Ticagrelor; Ticlopidine; Transfusion Reaction | 2014 |
Cangrelor: an emerging therapeutic option for patients with coronary artery disease.
Topics: Adenosine Monophosphate; Animals; Coronary Artery Disease; Humans; Randomized Controlled Trials as Topic | 2014 |
Cangrelor for treatment of arterial thrombosis.
Topics: Adenosine Monophosphate; Coronary Artery Disease; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents | 2014 |
[New antiplatelet drugs in coronary artery disease].
Topics: Adenosine; Adenosine Monophosphate; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Double-Blind Method; Dyspnea; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Treatment Outcome | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX).
Topics: Adenosine Monophosphate; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Survival Analysis; Treatment Outcome | 2014 |
New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Hemorrhage; Humans; Patents as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides | 2014 |
Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
Topics: Adenosine Monophosphate; Animals; Clinical Trials as Topic; Drug Approval; Forecasting; Humans; Infusions, Intravenous; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; United States | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
Topics: Adenosine Monophosphate; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis | 2015 |
Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor.
Topics: Adenosine Monophosphate; Advisory Committees; Congresses as Topic; Coronary Disease; Drug Approval; Humans; Purinergic P2Y Receptor Antagonists; United States; United States Food and Drug Administration | 2015 |
Cangrelor: A Review in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Blood Platelets; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Treatment Outcome | 2015 |
Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.
Topics: Adenosine Monophosphate; Administration, Oral; Blood Platelets; Coronary Artery Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Practice Guidelines as Topic | 2016 |
Cangrelor (Kengreal)--an IV antiplatelet drug for PCI.
Topics: Adenosine Monophosphate; Administration, Intravenous; Animals; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic | 2015 |
A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Topics: Adenosine Monophosphate; Aspirin; Drug Interactions; Drug Therapy, Combination; Half-Life; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists | 2016 |
Current status of data on cangrelor.
Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic | 2016 |
Type 2 Diabetes and ADP Receptor Blocker Therapy.
Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Why we need intravenous antiplatelet agents.
Topics: Adenosine Monophosphate; Aspirin; Blood Platelets; Humans; Injections, Intravenous; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists | 2016 |
Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents.
Topics: Adenosine; Adenosine Monophosphate; Imines; Lactones; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Quinazolinones; Sulfonamides; Ticagrelor | 2016 |
Cangrelor for the management and prevention of arterial thrombosis.
Topics: Adenosine Monophosphate; Administration, Intravenous; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticlopidine | 2016 |
New directions for pharmacotherapy in the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Antibodies, Monoclonal; Anticholesteremic Agents; Clinical Trials as Topic; Drug Discovery; Ezetimibe; Humans; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Treatment Outcome | 2016 |
Optimizing the Use of Cangrelor in the Real World.
Topics: Adenosine Monophosphate; Animals; Clinical Trials as Topic; Coronary Artery Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis | 2017 |
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Antithrombins; Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Genotype; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.
Topics: Adenosine Monophosphate; Animals; Cardiovascular Diseases; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12 | 2016 |
Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Coronary Artery Disease; Humans; Injections, Intravenous; Percutaneous Coronary Intervention; Postoperative Complications; Purinergic P2Y Receptor Antagonists | 2017 |
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
Topics: Adenosine Monophosphate; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2018 |
What is the Role of Cangrelor in Patients Undergoing PCI?
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Coronary Artery Disease; Coronary Thrombosis; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Treatment Outcome | 2018 |
Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.
Topics: Adenosine Monophosphate; Cardiovascular Surgical Procedures; Humans; Injections, Intravenous; Male; Middle Aged; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Treatment Outcome | 2019 |
Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Global Health; Humans; Percutaneous Coronary Intervention; Preoperative Care; Purinergic P2Y Receptor Antagonists; Survival Rate | 2019 |
Switching between P2Y
Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Cardiovascular Diseases; Clinical Decision-Making; Clopidogrel; Drug Substitution; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Treatment Outcome | 2019 |
P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Cangrelor in clinical use.
Topics: Adenosine Monophosphate; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Risk Factors; Treatment Outcome | 2020 |
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Animals; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thrombosis; Treatment Outcome | 2021 |
Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.
Topics: Adenosine Monophosphate; Eptifibatide; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Stents; Thromboembolism; Tirofiban | 2021 |
Safety and Efficacy of Cangrelor in Acute Stroke Treated with Mechanical Thrombectomy: Endovascular Treatment of Ischemic Stroke Registry and Meta-analysis.
Topics: Adenosine Monophosphate; Cerebral Hemorrhage; Combined Modality Therapy; Endovascular Procedures; Humans; Ischemic Stroke; Thrombectomy; Treatment Outcome | 2022 |
52 trial(s) available for adenosine monophosphate and cangrelor
| Article | Year |
|---|---|
Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Monophosphate; Adult; Aged; Angina, Unstable; Aspirin; Blood Coagulation Tests; Consumer Product Safety; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Heparin; Humans; Male; Membrane Proteins; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12 | 2001 |
Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction.
Topics: Adenosine Monophosphate; Aged; Angina, Unstable; Double-Blind Method; Female; Hemodynamics; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Myocardial Infarction; Platelet Aggregation | 2002 |
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Ticlopidine | 2002 |
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Topics: Abciximab; Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Double-Blind Method; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex | 2006 |
Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adolescent; Adult; Clopidogrel; Cyclooxygenase Inhibitors; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2008 |
Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angi
Topics: Adenosine Monophosphate; Coronary Angiography; Coronary Vessels; Drug Therapy, Combination; Electrocardiography; Fibrinolytic Agents; Humans; Infusions, Intravenous; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Tissue Plasminogen Activator; Vascular Patency | 2007 |
Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.
Topics: Adenosine Monophosphate; Adult; Female; Humans; Infusions, Intravenous; Injections, Intraventricular; Male; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12 | 2010 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Treatment Failure | 2009 |
Intravenous platelet blockade with cangrelor during PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Stents; Treatment Outcome | 2009 |
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Stents; Thienopyridines; Thrombosis | 2012 |
Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Survival Rate; Treatment Outcome | 2012 |
Effects on platelet function of a direct acting antagonist of coagulation factor Xa.
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Artery Disease; Crotalid Venoms; Factor Xa; Factor Xa Inhibitors; Female; Humans; Lectins, C-Type; Male; Middle Aged; Morpholines; Plant Proteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rivaroxaban; Thiophenes | 2012 |
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Antagonism; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Preoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2012 |
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
Topics: Adenosine Monophosphate; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Survival Analysis; Ticlopidine; Treatment Outcome | 2012 |
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2013 |
Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
Topics: Adenosine Monophosphate; Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Transfusion; Coronary Artery Bypass; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Injections, Intravenous; Male; Middle Aged; Placebo Effect; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Premedication; Prevalence; Purinergic P2Y Receptor Antagonists; Pyridines; Risk Assessment; Treatment Outcome; United States | 2013 |
Cangrelor in patients undergoing cardiac surgery: the BRIDGE study.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Coronary Artery Bypass; Double-Blind Method; Follow-Up Studies; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Time Factors; Treatment Outcome | 2013 |
Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Follow-Up Studies; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinolines; Time Factors; Young Adult | 2013 |
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Interv
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Intraoperative Complications; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Standard of Care; Stents; Thrombosis; Ticlopidine; Treatment Outcome | 2014 |
Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects.
Topics: Adenosine Monophosphate; Adult; Female; Gene Expression Regulation; Haplotypes; Humans; Male; P-Selectin; Peptide Fragments; Platelet Aggregation; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12 | 2014 |
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Topics: Adenosine Monophosphate; Aged; Blood Platelets; Cell Adhesion Molecules; Coronary Artery Disease; Drug Administration Schedule; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Time Factors | 2014 |
Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Cell Adhesion Molecules; Coronary Artery Disease; Drug Administration Schedule; Drug Interactions; Drug Substitution; Female; Humans; Infusions, Intravenous; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Vermont | 2014 |
Pharmacodynamic effects during the transition between cangrelor and prasugrel.
Topics: Adenosine Monophosphate; Administration, Oral; Aged; Coronary Artery Disease; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Time Factors; Treatment Outcome | 2015 |
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
Topics: Adenosine Monophosphate; Drug Overdose; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention | 2015 |
Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation.
Topics: Adenosine Monophosphate; Adult; Aged; Biological Availability; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2015 |
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femoral Artery; Graft Occlusion, Vascular; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Radial Artery; Stents; Ticlopidine; Treatment Outcome | 2016 |
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
Topics: Adenosine Monophosphate; Aged; Aged, 80 and over; Disease Management; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sex Characteristics; Treatment Outcome | 2016 |
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
Topics: Adenosine Monophosphate; Aged; Brazil; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Europe; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; New Zealand; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Thailand; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Disease Management; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2016 |
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; New Zealand; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome; United States | 2018 |
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; Treatment Outcome; United States | 2017 |
Randomized Comparison of Oral P2Y
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Disease; Drug Substitution; Female; Germany; Humans; Infusions, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Receptors, Purinergic P2Y12; Survival Analysis; Ticlopidine; Treatment Outcome; Withholding Treatment | 2017 |
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
Topics: Adenosine Monophosphate; Administration, Oral; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticlopidine; Time Factors | 2017 |
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y
Topics: Adenosine Monophosphate; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Drug Synergism; Humans; Microfilament Proteins; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Ticagrelor; Time Factors | 2017 |
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin; Humans; Intraoperative Period; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Retrospective Studies; Ticlopidine; Treatment Outcome | 2017 |
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2018 |
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor | 2018 |
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Female; Hemorrhage; Hospital Costs; Hospital Mortality; Humans; Length of Stay; Male; Middle Aged; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Time Factors; Treatment Outcome; United States | 2018 |
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPIO
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Perioperative Care; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; United States | 2018 |
Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Blood Platelets; Drug Therapy, Combination; Humans; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor | 2018 |
Platelet inhibition to target reperfusion injury trial: Rationale and study design.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Coronary Circulation; Double-Blind Method; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Treatment Outcome; Ventricular Remodeling; Young Adult | 2019 |
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.
Topics: Adenosine Monophosphate; Aged; Double-Blind Method; Female; Heart Diseases; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; ST Elevation Myocardial Infarction; Thrombosis; Treatment Outcome | 2019 |
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Double-Blind Method; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Combined Modality Therapy; Female; Humans; Male; Matched-Pair Analysis; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Shock, Cardiogenic | 2019 |
Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial.
Topics: Adenosine Monophosphate; Aged; Blood Platelets; Blood Vessels; Cells, Cultured; Female; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardium; Percutaneous Coronary Intervention; Platelet Activation; Platelet Function Tests; Receptors, Purinergic P2Y12; Regional Blood Flow; Ticagrelor | 2019 |
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and
Topics: Adenosine Monophosphate; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction.
Topics: Adenosine Monophosphate; Contrast Media; Gadolinium; Humans; Pancreatic Elastase; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2021 |
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
Topics: Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Treatment Outcome | 2022 |
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.
Topics: Adenosine Monophosphate; Hemorrhage; Humans; Myocardial Infarction; Obesity; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Treatment Outcome | 2022 |
246 other study(ies) available for adenosine monophosphate and cangrelor
| Article | Year |
|---|---|
Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.
Topics: Adenosine Monophosphate; Blood Platelets; Humans; Magnetic Resonance Spectroscopy; Membrane Proteins; Molecular Structure; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Spectrometry, Mass, Fast Atom Bombardment; Thrombosis | 1999 |
On the mechanism of plasmin-induced platelet aggregation. Implications of the dual role of granule ADP.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenylyl Cyclase Inhibitors; Apyrase; Blood Platelets; Calcium; Cell Degranulation; Drug Interactions; Epinephrine; Fibrinolysin; Fibrinolytic Agents; Humans; In Vitro Techniques; Ligands; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12 | 2000 |
The roles of P(2X1)and P(2T AC)receptors in ADP-evoked calcium signalling in human platelets.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Blood Platelets; Calcium Signaling; Humans; Membrane Proteins; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2X; Receptors, Purinergic P2Y12 | 2000 |
Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Arterial Occlusive Diseases; Bleeding Time; Blood Flow Velocity; Blood Platelets; Carotid Arteries; Carotid Artery Thrombosis; Disease Models, Animal; Dogs; Female; Hemodynamics; Injections, Intravenous; Male; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Tunica Intima | 2000 |
The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adenosine Monophosphate; Analysis of Variance; Annexin A5; Aspirin; Blood Platelets; Calcium; Collagen; Cytosol; Fibrinolytic Agents; Flow Cytometry; Humans; Membrane Proteins; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2X; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Serotonin; Stimulation, Chemical; Thromboxane A2 | 2000 |
ADP receptor antagonists inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Chemokine CCL17; Chemokine CCL22; Chemokine CXCL12; Chemokines, CC; Chemokines, CXC; Dose-Response Relationship, Drug; GTP-Binding Proteins; Humans; Inhibitory Concentration 50; Pertussis Toxin; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Thrombin; Time Factors; Virulence Factors, Bordetella | 2001 |
Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Cell Membrane; Cells, Cultured; Chemotaxis; Diffusion Chambers, Culture; Extracellular Space; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Proteins; Heterotrimeric GTP-Binding Proteins; Microglia; Pertussis Toxin; rac GTP-Binding Proteins; Rats; Rats, Wistar; Receptors, Purinergic P2; Virulence Factors, Bordetella | 2001 |
Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation.
Topics: Adaptation, Physiological; Adenosine Diphosphate; Adenosine Monophosphate; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Clopidogrel; Epinephrine; Female; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Protein alpha Subunits, Gq-G11; Heterotrimeric GTP-Binding Proteins; Hirudins; Humans; Male; Membrane Proteins; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Agonists; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-2; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Receptors, Serotonin; Recombinant Proteins; Serotonin; Serotonin Receptor Agonists; Ticlopidine | 2001 |
Differential regulation of Rho and Rac through heterotrimeric G-proteins and cyclic nucleotides.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Monophosphate; Animals; Apyrase; Blotting, Western; Cyclic AMP; Cyclic GMP; Electrophoresis, Polyacrylamide Gel; Heterotrimeric GTP-Binding Proteins; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; rac GTP-Binding Proteins; rho GTP-Binding Proteins | 2001 |
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Communication; Dipyridamole; Drug Synergism; Flow Cytometry; Humans; Leukocytes; Macrophage-1 Antigen; Monocytes; Neutrophils; P-Selectin; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors | 2001 |
Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Viscosity; Collagen Type I; Flow Cytometry; Hemorheology; Humans; Image Processing, Computer-Assisted; Membrane Proteins; Microscopy, Fluorescence; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12 | 2001 |
A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adenosine Monophosphate; Antigens, CD; Blood Platelets; Calcium; Chromatography, Gel; Cross-Linking Reagents; Dimerization; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epinephrine; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Platelet Aggregation Inhibitors; Protein Binding; rap GTP-Binding Proteins; Receptors, IgG; Recombinant Proteins; Serotonin; Signal Transduction; Time Factors | 2002 |
Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aged; Analysis of Variance; Blood Platelets; Humans; Male; Membrane Proteins; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombosis | 2002 |
Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome.
Topics: Adenosine Monophosphate; Adult; Amino Acid Sequence; Antibodies, Monoclonal; Female; Hermanski-Pudlak Syndrome; Humans; Membrane Proteins; Models, Biological; Molecular Sequence Data; Oligopeptides; Peptide Fragments; Platelet Aggregation; Puerto Rico; Purinergic P2 Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thrombin | 2002 |
Functional significance of adenosine 5'-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Cell Adhesion; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Membrane Proteins; Microscopy, Fluorescence; Microscopy, Video; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stress, Mechanical; von Willebrand Factor | 2002 |
Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Adhesion; Clopidogrel; Drug Therapy, Combination; Female; Humans; Leukocytes; Male; Membrane Proteins; Middle Aged; Myocardial Ischemia; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2002 |
A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Adrenergic Agonists; Androstadienes; Animals; Antimetabolites; Apyrase; Blood Platelets; Chromones; Dideoxyadenosine; Enzyme Inhibitors; Epinephrine; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Mice; Mice, Knockout; Morpholines; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Phosphoinositide-3 Kinase Inhibitors; Platelet Activation; Platelet Aggregation; Protein Binding; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; rap GTP-Binding Proteins; Receptors, Fc; Receptors, IgG; Second Messenger Systems; Wortmannin | 2003 |
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Animals; Bleeding Time; Blood Coagulation; Coronary Circulation; Coronary Restenosis; Coronary Stenosis; Disease Models, Animal; Dogs; Drug Combinations; Echocardiography; Female; Heparin; Infusions, Intravenous; Male; Membrane Proteins; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombosis; Tissue Plasminogen Activator | 2003 |
In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability.
Topics: Adenosine Monophosphate; Administration, Oral; Animals; Blood Platelets; Calcium; Clopidogrel; Female; Male; Membrane Proteins; Platelet Activation; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2Y12; Thrombin; Thromboembolism; Ticlopidine | 2003 |
The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions.
Topics: Abciximab; Adenosine Monophosphate; Antibodies, Monoclonal; Aspirin; Blood Platelets; CD11b Antigen; Dipyridamole; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Leukocytes; Monocytes; Neutrophils; Oligopeptides; Peptides, Cyclic; Platelet Glycoprotein GPIIb-IIIa Complex; Thiazolidines; Thromboplastin | 2003 |
Effects of inhibition of P2Y(1) and P2Y(12) on whole blood clotting, coagulum elasticity and fibrinolysis resistance studied with free oscillation rheometry.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adult; Blood Coagulation; Carrier Proteins; Elasticity; Fibrinolysis; Flow Cytometry; Hemorheology; Hirudins; Humans; Membrane Proteins; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Recombinant Proteins; Tissue Plasminogen Activator; Whole Blood Coagulation Time | 2003 |
Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Blood Platelets; Disease Models, Animal; Humans; Leukocytes; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; P-Selectin; Peptide Fragments; Phosphatidylserines; Plasma; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Thrombin; Thrombosis | 2003 |
Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Alprostadil; Calcium; Calcium Signaling; Clopidogrel; Cytoplasm; Dose-Response Relationship, Drug; Drug Synergism; Humans; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors | 2004 |
Effects of the NHE-1 inhibitor cariporide alone or together with the P2Y12 antagonist AR-C 69331 MX on CD62p expression and formation of platelet-leukocyte aggregates.
Topics: Adenosine Monophosphate; Blood Platelets; Cell Aggregation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Combinations; Guanidines; Humans; Leukocytes; Membrane Proteins; Neutrophil Activation; Osmosis; P-Selectin; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; Receptors, Pituitary Hormone; Receptors, Purinergic P2Y12; Sodium-Hydrogen Exchangers; Sulfones | 2003 |
Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Cattle; Collagen; Enzyme Activation; Epinephrine; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Integrin alpha2beta1; Membrane Proteins; Mitogen-Activated Protein Kinase 1; Phosphorylation; Platelet Aggregation; Platelet Membrane Glycoproteins; Protein Kinase C; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thromboxane A2, Prostaglandin H2; Signal Transduction; Thromboxane A2 | 2004 |
P2Y12 receptor stimulation inhibits beta-adrenergic receptor-induced differentiation by reversing the cyclic AMP-dependent inhibition of protein kinase B.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenylyl Cyclase Inhibitors; Adrenergic beta-Agonists; Animals; Cell Differentiation; Cell Division; Cell Line, Tumor; Cyclic AMP; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Glioma; GTP-Binding Protein alpha Subunits, Gi-Go; Membrane Proteins; Pertussis Toxin; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Rats; Receptors, Adrenergic, beta; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides | 2004 |
Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
Topics: Abciximab; Adenosine Diphosphate; Adenosine Monophosphate; Antibodies, Monoclonal; Aspirin; Blood Platelets; Cell Degranulation; Collagen; Drug Interactions; Humans; Immunoglobulin Fab Fragments; Membrane Proteins; Oligopeptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12 | 2004 |
P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aged; Diabetes Mellitus, Type 2; Female; Humans; Male; Membrane Proteins; Middle Aged; Piperazines; Piperidines; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values | 2005 |
Autoinhibition of transmitter release from PC12 cells and sympathetic neurons through a P2Y receptor-mediated inhibition of voltage-gated Ca2+ channels.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adenosine; Adenosine Monophosphate; Animals; Animals, Newborn; Cadmium; Calcium Channels; Cells, Cultured; Colforsin; Cyclic AMP; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Ganglia, Sympathetic; Membrane Potentials; Membrane Proteins; Neural Inhibition; Neurons; Norepinephrine; Patch-Clamp Techniques; PC12 Cells; Pertussis Toxin; Phenethylamines; Potassium; Purine Nucleotides; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Pyridoxal Phosphate; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Suramin; Thionucleosides; Tritium | 2004 |
Regulation of tissue factor-induced coagulation and platelet aggregation in flowing whole blood.
Topics: Adenosine Monophosphate; Alprostadil; Animals; Blood Coagulation; Disease Models, Animal; Drug Interactions; Fibrin; Fibrinogen; Fibrinolytic Agents; Male; Perfusion; Phosphatidylserines; Platelet Activation; Platelet Aggregation; Rats; Rats, Wistar; Thrombin; Thromboplastin | 2005 |
Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.
Topics: Actins; Adenosine Diphosphate; Adenosine Monophosphate; Adult; Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Female; Flow Cytometry; Humans; Male; Membrane Proteins; Microfilament Proteins; Middle Aged; Myocardial Ischemia; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors | 2005 |
Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Degranulation; Dalteparin; Drug Synergism; Heparin; Hirudins; Humans; In Vitro Techniques; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12 | 2005 |
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Topics: Adenosine Monophosphate; Calcium Signaling; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Ticlopidine | 2005 |
P2Y12 ADP receptor-dependent tyrosine phosphorylation of proteins of 27 and 31 kDa in thrombin-stimulated human platelets.
Topics: Adenine; Adenosine Diphosphate; Adenosine Monophosphate; Adenylyl Cyclases; Aspirin; Blood Platelets; Collagen; Cyclic AMP; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Epinephrine; Epoprostenol; Humans; Membrane Proteins; Oligopeptides; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Signal Transduction; Thrombin; Time Factors; Tyrosine | 2005 |
Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.
Topics: Abciximab; Adenosine Monophosphate; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Eptifibatide; Hirudins; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Sensitivity and Specificity; Ticlopidine | 2005 |
Metabotropic P2Y1 receptors inhibit P2X3 receptor-channels in rat dorsal root ganglion neurons.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Animals, Newborn; Cells, Cultured; Dose-Response Relationship, Drug; Ganglia, Spinal; Guanosine 5'-O-(3-Thiotriphosphate); Male; Membrane Potentials; Neurons; Patch-Clamp Techniques; Pertussis Toxin; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P2; Receptors, Purinergic P2X3; Receptors, Purinergic P2Y1; Thionucleotides | 2005 |
The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Endocytosis; Humans; Lipoproteins, HDL; Liver; Male; Mice; Mice, Inbred C57BL; Perfusion; Receptors, Purinergic P2 | 2005 |
Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Topics: Abciximab; Adenosine Monophosphate; Antibodies, Monoclonal; Aspirin; Blood Platelets; CD40 Ligand; Coagulants; Humans; Immunoglobulin Fab Fragments; Membrane Proteins; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thrombin; Secretory Vesicles; Tirofiban; Tyrosine | 2005 |
Evidence that the purinergic receptor P2Y12 potentiates platelet shape change by a Rho kinase-dependent mechanism.
Topics: Actins; Adenosine Diphosphate; Adenosine Monophosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Androstadienes; Blood Platelets; Calcium; Cell Shape; Chelating Agents; Egtazic Acid; Enzyme Activation; Enzyme Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Myosins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet Activation; Protein Serine-Threonine Kinases; Pseudopodia; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; rho-Associated Kinases; Second Messenger Systems; Wortmannin | 2005 |
Evaluation of platelet function, a method comparison.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Platelet Activation; Platelet Aggregation; Platelet Count; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Fibrinogen; Reference Values; Regression Analysis; Sensitivity and Specificity; Time Factors | 2006 |
Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
Topics: Adenosine Monophosphate; Blood Platelets; Calcium Channel Blockers; Calcium Signaling; Collagen; Humans; In Vitro Techniques; Lanthanum; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Thrombosis; Tirofiban; Tyrosine | 2006 |
P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation.
Topics: Adenosine Monophosphate; Animals; Blood Platelets; Butadienes; Clopidogrel; Enzyme Inhibitors; Humans; Membrane Proteins; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Nitriles; Phospholipases A; Phospholipases A2; Platelet Aggregation Inhibitors; Pyrimidines; Receptor, PAR-1; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thrombin; Signal Transduction; src-Family Kinases; Thrombin; Thromboxane A2; Ticlopidine | 2006 |
Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: association with Rap1B activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adenosine Monophosphate; Antibodies, Monoclonal; Blood Platelets; Dose-Response Relationship, Drug; Humans; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Kinase C; Purinergic P2 Receptor Antagonists; rap GTP-Binding Proteins; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Signal Transduction; Thrombin | 2006 |
Can the PFA-100 be modified to detect P2Y12 inhibition?
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Monitoring; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticlopidine | 2006 |
Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents.
Topics: Adenosine Monophosphate; Analysis of Variance; Anticoagulants; Antithrombin III; Blood Platelets; CD11b Antigen; Complement Activation; Drug Delivery Systems; Factor XIa; Factor XIIa; Flow Cytometry; Heparin; Humans; In Vitro Techniques; Membrane Proteins; Peptide Hydrolases; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents | 2006 |
Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; In Vitro Techniques; Light; Male; Microfilament Proteins; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reproducibility of Results | 2006 |
Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenylyl Cyclases; Blood Platelets; Cyclic AMP; Cyclic CMP; Deoxyadenine Nucleotides; Dose-Response Relationship, Drug; Drug Synergism; Epoprostenol; Humans; In Vitro Techniques; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Serotonin; Thrombin | 2007 |
Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Antibodies, Monoclonal; Aspirin; Atherosclerosis; Blood Coagulation Tests; Blood Platelets; Carotid Stenosis; Dose-Response Relationship, Drug; Hemorheology; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Thrombosis; Time Factors; von Willebrand Factor | 2007 |
Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Benzothiazoles; Blood Platelets; Coronary Disease; Crotalid Venoms; Flow Cytometry; Fluorescent Dyes; Hemostatics; Humans; Lectins, C-Type; Platelet Activating Factor; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Quinolines; Thrombin; Tirofiban; Tyrosine | 2007 |
Enhanced platelet aggregation and activation under conditions of hypothermia.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Antigens, CD; Aspirin; Blood Platelets; Blood Specimen Collection; Citrates; Cold Temperature; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Hirudins; Humans; Hypothermia, Induced; In Vitro Techniques; P-Selectin; Platelet Activating Factor; Platelet Activation; Platelet Aggregation; Platelet Function Tests; Platelet Membrane Glycoproteins; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thrombin; Tetraspanin 30; Time Factors | 2007 |
Akt activation is involved in P2Y12 receptor-mediated chemotaxis of microglia.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Animals, Newborn; Calcium; Cells, Cultured; Cerebral Cortex; Chemotaxis; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Membrane Proteins; Microglia; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Signal Transduction; Type C Phospholipases | 2008 |
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Topics: Adenosine Monophosphate; Adult; Annexin A5; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytoplasmic Granules; Humans; In Vitro Techniques; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Calcium; Cell Adhesion Molecules; Cell Shape; Coenzyme A; Fibrinolytic Agents; Humans; Microfilament Proteins; Palmitoyl Coenzyme A; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12 | 2008 |
P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury.
Topics: Adenosine Monophosphate; Administration, Oral; Animals; Clopidogrel; Hyperesthesia; Injections, Spinal; Male; Membrane Proteins; Mice; Mice, Knockout; Microglia; Neuralgia; Purinergic P2 Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Spinal Cord; Spinal Nerves; Ticlopidine; Up-Regulation | 2008 |
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
Multiple electrode aggregometry and P2Y(12) antagonists.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Electrodes; Equipment Design; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Binding Sites; Computer Simulation; Crystallography, X-Ray; Humans; Models, Molecular; Purinergic P2 Receptor Antagonists; Rats; Receptors, G-Protein-Coupled; Receptors, Purinergic P2; Structural Homology, Protein; Uridine Diphosphate | 2008 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Blood Platelets; Cell Adhesion Molecules; Dinoprostone; Humans; Immunoblotting; Microfilament Proteins; Microscopy, Confocal; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Count; Purinergic P2 Receptor Agonists; Rats; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; Receptors, Purinergic P2; Uridine Diphosphate Glucose | 2008 |
Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Amino Acid Motifs; Animals; Binding Sites; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides | 2008 |
RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenoviridae; Apolipoprotein A-I; Cell Line; Cell Membrane; Endocytosis; Hepatocytes; Humans; Lipoproteins, HDL; Proton-Translocating ATPases; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2; rho-Associated Kinases; rhoA GTP-Binding Protein; RNA, Small Interfering; Signal Transduction | 2009 |
Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adrenergic alpha-Antagonists; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Norepinephrine; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Adrenergic, alpha-2; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Failure | 2008 |
DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.
Topics: Acrylamides; Adenosine Monophosphate; Aspirin; Atherosclerosis; Blood Platelets; Cells, Cultured; Dinoprostone; Drug Interactions; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; Receptors, Purinergic P2Y12; Sulfones | 2008 |
Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Blood Platelets; Clinical Trials as Topic; Coronary Artery Disease; Crotalid Venoms; Drug Evaluation, Preclinical; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Flow Cytometry; Heparin; Hirudins; Humans; Lectins, C-Type; P-Selectin; Peptide Fragments; Peptides; Pilot Projects; Platelet Activating Factor; Platelet Activation; Platelet Function Tests; Recombinant Proteins; Research Design; Thrombin | 2009 |
Mechanism of activation and functional role of protein kinase Ceta in human platelets.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Blood Platelets; Enzyme Activation; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Integrin alpha2; Mice; Mice, Knockout; Peptides, Cyclic; Phosphorylation; Platelet Aggregation; Protein Kinase C; Protein Phosphatase 1; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Thromboxanes | 2009 |
The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Blood Platelets; Cyclic AMP; Dose-Response Relationship, Drug; GTP-Binding Protein alpha Subunits, Gi-Go; Guanosine Diphosphate; Humans; In Vitro Techniques; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Receptor, Adenosine A2A; Receptor, PAR-1; Receptors, Epoprostenol; Receptors, Immunologic; Receptors, Prostaglandin; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Purinergic P2Y12; Receptors, Thromboxane A2, Prostaglandin H2; Signal Transduction; Thionucleotides | 2009 |
Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Drug Monitoring; Female; Flow Cytometry; Humans; Male; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Tissue Fixation | 2009 |
Cangrelor - a champion lost in translation?
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Humans; Platelet Aggregation Inhibitors; Research Design; Treatment Failure | 2009 |
Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Flow Cytometry; Humans; Iloprost; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Epoprostenol; Receptors, Purinergic P2Y12; Ticlopidine; Young Adult | 2010 |
Two-pore potassium ion channels are inhibited by both G(q/11)- and G(i)-coupled P2Y receptors.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Analysis of Variance; Cell Line; Cells, Cultured; Electrophysiology; Humans; Ion Channel Gating; Membrane Potentials; Potassium Channels, Tandem Pore Domain; Receptors, Purinergic P2 | 2010 |
The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor.
Topics: Adenosine Monophosphate; Adult; Blood Platelets; Female; Genotype; Humans; Middle Aged; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12 | 2010 |
Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Platelet inhibition with cangrelor.
Topics: Adenosine Monophosphate; Administration, Oral; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Infusions, Intravenous; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2010 |
Platelet inhibition with cangrelor.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Research Design; Ticlopidine | 2010 |
Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts.
Topics: Abciximab; Adenosine Monophosphate; Animals; Antibodies, Monoclonal; Blood Platelets; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Myocardium; P-Selectin; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reperfusion Injury; Ventricular Function, Left | 2010 |
Enhanced platelet reactivity and thrombosis in Apoe-/- mice exposed to cigarette smoke is attenuated by P2Y12 antagonism.
Topics: Adenosine Monophosphate; Animals; Apolipoproteins E; Blood Platelets; Chlorides; Female; Ferric Compounds; Fibrinogen; Gene Deletion; Mice; Mice, Inbred C57BL; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Tobacco Smoke Pollution | 2010 |
Testing a new approach for rapid and reversible platelet inhibition during percutaneous coronary intervention among patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Stents; Treatment Outcome | 2010 |
Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; DNA Mutational Analysis; Humans; Ligands; Mutagenesis, Site-Directed; Protein Binding; Receptors, Purinergic P2Y12 | 2010 |
Nerve injury-activated microglia engulf myelinated axons in a P2Y12 signaling-dependent manner in the dorsal horn.
Topics: Adenosine Monophosphate; Animals; Calcium-Binding Proteins; Cell Proliferation; Disease Models, Animal; Functional Laterality; Gene Expression Regulation; Hyperalgesia; Male; Microfilament Proteins; Microglia; Microscopy, Immunoelectron; Nerve Fibers, Myelinated; Neuralgia; Posterior Horn Cells; Purinergic P2Y Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P2Y12; Signal Transduction; Spinal Cord; Spinal Nerves | 2010 |
SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys.
Topics: Adenosine Monophosphate; Animals; Disease Models, Animal; Drug Therapy, Combination; Fibrinolytic Agents; Macaca fascicularis; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thrombosis | 2010 |
BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
Topics: Adenine; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Blood Platelets; CHO Cells; Coronary Artery Disease; Cricetinae; Cricetulus; Humans; Mice; Mice, Knockout; Phosphoric Diester Hydrolases; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2Y12 | 2010 |
P2Y13 receptor is critical for reverse cholesterol transport.
Topics: Adenosine Monophosphate; Animals; Biological Transport; Cholesterol; Cholesterol, HDL; Lipoproteins, HDL; Mice; Mice, Knockout; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2; Scavenger Receptors, Class B | 2010 |
The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Biological Assay; Biomarkers; Blood Platelets; Case-Control Studies; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Sensitivity and Specificity; Ticlopidine; Young Adult | 2011 |
Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, G-Protein-Coupled; Thiophenes; Ticagrelor | 2011 |
Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Erythrocytes; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor | 2011 |
High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner.
Topics: Adenosine Monophosphate; Aged; Angioplasty; Clinical Protocols; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Function Tests; Predictive Value of Tests; Reproducibility of Results; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2011 |
Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade.
Topics: Adenosine Monophosphate; Adult; Aged; Cell Adhesion Molecules; Clopidogrel; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2011 |
P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Topics: Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Adhesion Molecules; Cyclic AMP; Humans; Microfilament Proteins; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandins E; Purinergic P2Y Receptor Antagonists; Receptors, Prostaglandin E, EP3 Subtype; Receptors, Purinergic P2Y12 | 2011 |
Nucleotides control the excitability of sensory neurons via two P2Y receptors and a bifurcated signaling cascade.
Topics: Action Potentials; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Animals, Newborn; Calcium; Capsaicin; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Enzyme Inhibitors; Estrenes; Ganglia, Spinal; Ion Channel Gating; Nucleotides; Patch-Clamp Techniques; Purinergic P2Y Receptor Agonists; Purinergic P2Y Receptor Antagonists; Pyrrolidinones; Rats; Receptors, Purinergic P2Y; Sensory Receptor Cells; Signal Transduction; Statistics, Nonparametric; TRPV Cation Channels; Type C Phospholipases | 2011 |
BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.
Topics: Adenosine; Adenosine Monophosphate; Animals; Disease Models, Animal; Drug Synergism; Enzyme Inhibitors; Fibrinolytic Agents; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phosphoric Diester Hydrolases; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis | 2011 |
Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Apyrase; Arachidonic Acid; Cell Degranulation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Peptide Fragments; Platelet Adhesiveness; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Reproducibility of Results; Signal Transduction | 2011 |
Short-acting P2Y12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Antithrombin III; Blood Coagulation Disorders; Blood Platelets; Cardiopulmonary Bypass; Cytoplasmic Granules; Extracorporeal Circulation; Humans; Hypothermia, Induced; Peptide Hydrolases; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Swine | 2012 |
Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12.
Topics: Adenosine Monophosphate; Animals; Bleeding Time; Blood Platelets; Chlorides; Cyclic AMP; Disease Models, Animal; Drug Inverse Agonism; Ferric Compounds; Fibrinolytic Agents; Genotype; Mice; Mice, Transgenic; Phenotype; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-akt; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis | 2012 |
Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Topics: Adenosine; Adenosine Monophosphate; Animals; Blood Platelets; Clopidogrel; Dogs; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2012 |
Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.
Topics: Adenosine Monophosphate; Aged; Coronary Artery Disease; Diabetes Complications; Female; Humans; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2013 |
Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts.
Topics: Adenosine Monophosphate; Animals; Cardiotonic Agents; Clopidogrel; Coronary Vessels; Female; Heart; In Vitro Techniques; Ischemic Postconditioning; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Perfusion; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Purinergic P2Y Receptor Antagonists; Rabbits; Receptors, Purinergic P2Y12; Signal Transduction; Ticlopidine | 2013 |
The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Blood Platelets; Cell Adhesion Molecules; Colforsin; Cyclic AMP; Epoprostenol; Mice; Mice, Knockout; Microfilament Proteins; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-akt; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y; Signal Transduction; Thionucleosides | 2012 |
Chronic pharmacological activation of P2Y13 receptor in mice decreases HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion.
Topics: Adenosine Monophosphate; Animals; Bile Acids and Salts; Biological Transport; Cholesterol, HDL; Lipoproteins, HDL; Liver; Mice; Purinergic P2Y Receptor Agonists; Receptors, Purinergic P2 | 2013 |
Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Antigens, CD; Blood Platelets; Fibrin; GTP-Binding Protein alpha Subunit, Gi2; Hemostasis; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Semaphorins; Signal Transduction; Thrombin | 2013 |
Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts.
Topics: Adenosine Monophosphate; Animals; Antibodies; Blood Pressure; Heart Rate; Macaca fascicularis; Male; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Purinergic P2Y Receptor Antagonists | 2013 |
Deciphering of ADP-induced, phosphotyrosine-dependent signaling networks in human platelets by Src-homology 2 region (SH2)-profiling.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cyclic AMP-Dependent Protein Kinases; Enzyme Activation; Humans; Iloprost; Phosphorylation; Phosphotyrosine; Platelet Activation; Protein Processing, Post-Translational; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Signal Transduction; src Homology Domains; Tandem Mass Spectrometry | 2013 |
Cardioprotection--time to take into account clinical complexity: the case of antiplatelet agents : editorial to "two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts" by Xi-Ming Yang et al.
Topics: Adenosine Monophosphate; Animals; Antibodies; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Purinergic P2Y Receptor Antagonists | 2013 |
A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Biomarkers; Creatine Kinase, MB Form; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Troponin | 2013 |
The duel between dual antiplatelet therapies.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2013 |
Periprocedural type IVa myocardial infarction and the importance of platelet inhibition.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Creatine Kinase, MB Form; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Troponin | 2013 |
Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.
Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Clopidogrel; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome | 2013 |
Study ignites debate on new anticoagulant.
Topics: Adenosine Monophosphate; Drug Approval; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart.
Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Arrhythmia Agents; Cardiotonic Agents; Guanidines; Hypothermia, Induced; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Sulfones; Ticagrelor | 2013 |
P2Y12 platelet receptors: importance in percutaneous coronary intervention.
Topics: Adenosine; Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Thiophenes; Ticagrelor | 2013 |
Cangrelor: a new CHAMPION for percutaneous coronary intervention.
Topics: Adenosine Monophosphate; Female; Humans; Male; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2013 |
[The CHAMPION PHOENIX study].
Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Double-Blind Method; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Ticlopidine | 2013 |
Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry?
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Blood Platelets; Collagen; Female; Flow Cytometry; Mice; Models, Animal; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Thrombin | 2013 |
Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge.
Topics: Adenosine Monophosphate; Blood Platelets; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
The elusive disconnection between mortality and early stent thrombosis: observations from the CHAMPION-PHOENIX trial.
Topics: Adenosine Monophosphate; Blood Platelets; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic | 2014 |
Cangrelor for treatment during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Coronary Thrombosis; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Stents | 2014 |
Expression of dual nucleotides/cysteinyl-leukotrienes receptor GPR17 in early trafficking of cardiac stromal cells after myocardial infarction.
Topics: Adenosine Monophosphate; Animals; Antigens, Ly; Cell Movement; Hyaluronan Receptors; Leukocyte Common Antigens; Leukotriene D4; Membrane Proteins; Mesenchymal Stem Cells; Mice, Inbred C57BL; Myocardial Infarction; Nerve Tissue Proteins; Purinergic P2Y Receptor Antagonists; Receptors, G-Protein-Coupled; Uridine Diphosphate Glucose | 2014 |
P2Y₁ and P2Y₁₂ receptors in hypoxia- and adenosine diphosphate-induced pulmonary vasoconstriction in vivo in the pig.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Blood Pressure; Deoxyadenine Nucleotides; Hypertension, Pulmonary; Hypoxia; Pulmonary Artery; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Swine; Vasoconstriction | 2014 |
Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion.
Topics: Adenosine Monophosphate; Animals; Deoxyribonuclease I; Disease Models, Animal; Endodeoxyribonucleases; Hemodynamics; Male; Mitochondria; Myocardial Infarction; Myocardial Reperfusion Injury; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Recombinant Fusion Proteins | 2015 |
Thrombin-induced lysosomal exocytosis in human platelets is dependent on secondary activation by ADP and regulated by endothelial-derived substances.
Topics: Acetylglucosaminidase; Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Epoprostenol; Exocytosis; Humans; Lysosomal Membrane Proteins; Lysosomes; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thrombin | 2016 |
Cardioprotective Properties of the Platelet P2Y12 Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood.
Topics: Adenosine Monophosphate; Animals; Blood Platelets; Cardiotonic Agents; Diabetes Complications; Dose-Response Relationship, Drug; Humans; Male; Mice; Myocardial Ischemia; Myocardial Reperfusion Injury; Purinergic P2Y Receptor Antagonists; Rats; Rats, Inbred Strains; Receptors, Purinergic P2Y12 | 2015 |
Cangrelor approved for use during coronary angioplasty.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug Approval; Humans; Infusions, Intravenous; Intraoperative Care; Platelet Aggregation Inhibitors; United States; United States Food and Drug Administration | 2015 |
Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
Topics: Adenosine Monophosphate; Binding, Competitive; Clopidogrel; Humans; In Vitro Techniques; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2016 |
Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Topics: Adenine; Adenosine Monophosphate; Agammaglobulinaemia Tyrosine Kinase; Blood Platelets; Calcium Signaling; Collagen; Dose-Response Relationship, Drug; Fibrinogen; Hemorrhage; Hemostasis; Humans; Piperidines; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyrimidines; Risk Factors; Time Factors | 2015 |
Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adult; Animals; Aspirin; Blood Coagulation; Blood Platelets; Coronary Thrombosis; Dinucleoside Phosphates; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Rats, Sprague-Dawley; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Time Factors; Young Adult | 2016 |
Quantification of the Blood Platelet Reactivity in the ADP-Induced Model of Non-Lethal Pulmonary Thromboembolism in Mice with the Use of Laser Doppler Flowmetry.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Area Under Curve; Blood Platelets; Eptifibatide; Intravital Microscopy; Laser-Doppler Flowmetry; Lung; Male; Mesentery; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pulmonary Embolism; Thrombocytopenia | 2016 |
Cangrelor-Mediated Cardioprotection Requires Platelets and Sphingosine Phosphorylation.
Topics: Adenosine Monophosphate; Animals; Blood Platelets; Cardiotonic Agents; Heart; Ischemic Postconditioning; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Protective Agents; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Sphingosine | 2016 |
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial.
Topics: Adenosine Monophosphate; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Research Design | 2016 |
Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs.
Topics: Abciximab; Adenosine; Adenosine Monophosphate; Animals; Antibodies, Monoclonal; Cattle; Clopidogrel; Dimethylpolysiloxanes; Equipment Design; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Lab-On-A-Chip Devices; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Powders; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Serum Albumin, Bovine; Ticagrelor; Ticlopidine | 2016 |
A promiscuous recognition mechanism between GPR17 and SDF-1: Molecular insights.
Topics: Adenosine Monophosphate; Animals; Cells, Cultured; Chemokine CXCL12; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled | 2016 |
Cangrelor Bridge Therapy for Gastroduodenal Biopsy.
Topics: Adenosine Monophosphate; Administration, Intravenous; Biopsy; Clopidogrel; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2017 |
P2Y13 receptors mediate presynaptic inhibition of acetylcholine release induced by adenine nucleotides at the mouse neuromuscular junction.
Topics: Acetylcholine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Female; Male; Mice; Miniature Postsynaptic Potentials; Neuromuscular Junction; Purinergic P2 Receptor Agonists; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides | 2016 |
New Drugs 2016, part 3.
Topics: Adenosine Monophosphate; Aminopyridines; Anti-Asthmatic Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiemetics; Benzodioxoles; Cholagogues and Choleretics; Cystic Fibrosis Transmembrane Conductance Regulator; Deoxycholic Acid; Diarrhea; Drug Approval; Imidazoles; Irritable Bowel Syndrome; Spiro Compounds | 2016 |
Periprocedural platelet inhibition with cangrelor in P2Y
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Aged; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2016 |
Cangrelor: Fixing Life or Just a Leak?
Topics: Adenosine Monophosphate; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2016 |
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
Topics: Adenosine; Adenosine Monophosphate; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2017 |
Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital.
Topics: Adenosine Monophosphate; Aged; Coronary Artery Disease; Drug Approval; Female; Humans; Injections, Intravenous; Intraoperative Period; Male; Middle Aged; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Tertiary Care Centers; United States; United States Food and Drug Administration | 2017 |
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Cangrelor: The Paradox of Choice.
Topics: Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Platelet Glycoprotein GPIIb-IIIa Complex | 2017 |
Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Dose-Response Relationship, Drug; Humans; Kinetics; Microfilament Proteins; P-Selectin; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Ticagrelor | 2017 |
Synthesis and Ability of New Ligands for G Protein-Coupled Receptors 17 (GPR17).
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Binding Sites; Chromatography, Affinity; Humans; Immobilized Proteins; Ligands; Models, Molecular; Protein Binding; Receptors, G-Protein-Coupled | 2017 |
The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes.
Topics: Adenosine; Adenosine Monophosphate; Animals; Cell Membrane; CHO Cells; Cricetinae; Cricetulus; Cysteine; HEK293 Cells; Humans; Leukotrienes; Ligands; Mice; Nerve Tissue Proteins; Rats; Receptors, G-Protein-Coupled; Signal Transduction; Small Molecule Libraries; Ticagrelor; Uracil Nucleotides | 2017 |
Contribution of platelet P2Y
Topics: Adenosine Monophosphate; Aniline Compounds; Animals; Blood Platelets; Chemokine CXCL1; Chronic Pain; Cytokines; Freund's Adjuvant; Furans; Hyperalgesia; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pain; Receptors, Purinergic P2Y12; Time Factors; Tumor Necrosis Factor-alpha | 2017 |
Platelets Express Activated P2Y
Topics: Adenosine Monophosphate; Animals; Blood Platelets; Cell Adhesion Molecules; Cell Line; Chlorides; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Inverse Agonism; Ferric Compounds; Fibrinolytic Agents; Humans; Male; Microfilament Proteins; NF-kappa B; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Reactive Oxygen Species; Receptors, Purinergic P2Y12; Thrombosis | 2017 |
Maintenance of Drug-Eluting Stent Patency Through Use of a Cangrelor Infusion in the Clinical Setting of Massive Pulmonary Hemorrhage and Venoarterial Extracorporeal Membrane Oxygenation.
Topics: Adenosine Monophosphate; Combined Modality Therapy; Drug-Eluting Stents; Electrocardiography; Extracorporeal Membrane Oxygenation; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Pulmonary Edema | 2017 |
Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Aged; Cardiotonic Agents; Female; Gene Expression; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y; Shock, Cardiogenic; Survival Analysis | 2017 |
Cangrelor Use in Cardiogenic Shock: A Single-Center Real-World Experience.
Topics: Adenosine Monophosphate; Humans; Shock, Cardiogenic; Stents; Treatment Outcome | 2017 |
Pharmacosimulation of interruptions and its solution in intravenous administration of cangrelor.
Topics: Adenosine Monophosphate; Administration, Intravenous; Female; Humans; Male; Platelet Aggregation Inhibitors | 2018 |
Research Correspondence: One Good Point, One Great Figure (or Table).
Topics: Adenosine Monophosphate; Humans; Shock, Cardiogenic; Treatment Outcome | 2017 |
Cangrelor or Abciximab as First Choice in Cardiogenic Shock.
Topics: Abciximab; Adenosine Monophosphate; Humans; Immunoglobulin Fab Fragments; Shock, Cardiogenic | 2017 |
Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock.
Topics: Abciximab; Adenosine Monophosphate; Humans; Immunoglobulin Fab Fragments; Shock, Cardiogenic | 2017 |
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thrombocytopenia; Time Factors; Treatment Outcome | 2018 |
Hobson's Choice: Platelet Inhibition and Thrombocytopenia.
Topics: Adenosine Monophosphate; Blood Platelets; Humans; Incidence; Percutaneous Coronary Intervention; Thrombocytopenia | 2018 |
The use of cangrelor with heparin for left ventricular assist device implantation in a patient with acute heparin-induced thrombocytopenia.
Topics: Acute Disease; Adenosine Monophosphate; Anticoagulants; Blood Coagulation Disorders; Cardiopulmonary Bypass; Drug Therapy, Combination; Heart-Assist Devices; Heparin; Humans; Intraoperative Complications; Male; Middle Aged; Platelet Aggregation Inhibitors; Prosthesis Implantation; Thrombocytopenia | 2018 |
The Use of Cangrelor and Heparin for Anticoagulation in a Patient Requiring Pulmonary Thromboendarterectomy Surgery with Suspected Heparin-Induced Thrombocytopenia.
Topics: Adenosine Monophosphate; Anticoagulants; Blood Coagulation; Drug Therapy, Combination; Endarterectomy; Heparin; Humans; Male; Platelet Aggregation Inhibitors; Thrombocytopenia; Young Adult | 2019 |
Cangrelor use prior to left ventricular assist device surgery: a case series.
Topics: Adenosine Monophosphate; Aged; Cardiovascular Surgical Procedures; Female; Heart Ventricles; Heart-Assist Devices; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Shock, Cardiogenic | 2018 |
Optimal platelet inhibition with cangrelor in comatose survivors of out-of-hospital cardiac arrest undergoing primary percutaneous coronary intervention.
Topics: Adenosine Monophosphate; Biological Availability; Coma; Female; Humans; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2018 |
Cangrelor alleviates pulmonary fibrosis by inhibiting GPR17-mediated inflammation in mice.
Topics: Adenosine Monophosphate; Animals; Bleomycin; Cell Survival; Dose-Response Relationship, Drug; Inflammation; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Pulmonary Fibrosis; RAW 264.7 Cells; Receptors, G-Protein-Coupled; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2018 |
Pharmacodynamic-Guided Cangrelor Bridge Therapy for Orthotopic Heart Transplant.
Topics: Adenosine Monophosphate; Aged; Coronary Artery Disease; Heart Transplantation; Humans; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Preoperative Care | 2019 |
Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
Topics: Adenosine Monophosphate; Administration, Oral; Aged; Aged, 80 and over; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Care; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Treatment Outcome | 2019 |
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
Topics: Adenosine; Adenosine A2 Receptor Agonists; Adenosine Monophosphate; Adult; Blood Platelets; Dose-Response Relationship, Drug; Female; Furans; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Young Adult | 2019 |
Effect of P2Y
Topics: Adenosine Monophosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Fibrin Clot Lysis Time; Fibrinolysis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2019 |
Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Combination; Endovascular Procedures; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Stroke; Thrombectomy; Treatment Outcome | 2019 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Use of Cangrelor as a Bridge to Left Ventricular Assist Device Implantation in a Patient with a Recent Drug-Eluting Stent Who Developed Acute Tirofiban-Related Thrombocytopenia.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Dose-Response Relationship, Drug; Drug-Eluting Stents; Heart-Assist Devices; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Thrombocytopenia; Tirofiban; Treatment Outcome; Ventricular Dysfunction, Left | 2019 |
intravenous cangrelor (Kengrexal°) and coronary angioplasty: No advantage over first-line clopidogrel.
Topics: Adenosine Monophosphate; Administration, Intravenous; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2016 |
Successful Use of Cangrelor and Heparin for Cardiopulmonary Bypass in a Patient With Heparin-Induced Thrombocytopenia and End-Stage Renal Disease: A Case Report.
Topics: Adenosine Monophosphate; Cardiopulmonary Bypass; Female; Heart Valve Prosthesis Implantation; Heparin; Humans; Intraoperative Care; Kidney Failure, Chronic; Middle Aged; Thrombocytopenia; Treatment Outcome | 2019 |
Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Topics: Adenosine Monophosphate; Aged; Coronary Thrombosis; Drug Utilization; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Sweden; Time Factors; Treatment Outcome | 2019 |
Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Coronary Angiography; Coronary Thrombosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Treatment Outcome | 2019 |
Cangrelor Bridging Within 6 Months of a Drug-Eluting Stent in a Patient for Emergency Cervical Spine Surgery: A Case Report.
Topics: Accidental Falls; Accidental Injuries; Adenosine Monophosphate; Aged; Cervical Cord; Diskectomy; Drug-Eluting Stents; Humans; Male; Platelet Aggregation Inhibitors; Spinal Fusion | 2019 |
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Stents; Time Factors; Treatment Outcome | 2019 |
Cangrelor for ST-Segment-Elevation Myocardial Infarction.
Topics: Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Anti-platelet therapy and the anaesthesiologist: controversies and unresolved clinical dilemmas continue.
Topics: Adenosine Monophosphate; Anesthesiologists; Blood Platelets; Humans; Platelet Aggregation Inhibitors; Prospective Studies | 2019 |
A study on structural characterization of degradation products of cangrelor using LC/QTOF/MS/MS and NMR.
Topics: Adenosine Monophosphate; Chromatography, Liquid; Hydrolysis; Magnetic Resonance Spectroscopy; Oxidation-Reduction; Photolysis; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2019 |
Bridging antiplatelet therapy with cangrelor in patients with recent intracranial stenting undergoing invasive procedures: a prospective case series.
Topics: Adenosine Monophosphate; Aspirin; Brain; Female; Fibrinolytic Agents; Humans; Intracranial Aneurysm; Intracranial Thrombosis; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Stents | 2019 |
Acute myocardial infarction complicating ischemic stroke: is there room for cangrelor?
Topics: Adenosine Monophosphate; Aged; Aged, 80 and over; Biomarkers; Disease Management; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Time-to-Treatment; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Cangrelor for the Rescue of Intra-Procedural Stent Thrombosis in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Female; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Treatment Outcome | 2019 |
Expanding the Treatment of Calcified Lesions.
Topics: Adenosine Monophosphate; Atherectomy, Coronary; Humans; Percutaneous Coronary Intervention; Stents; Thrombosis | 2019 |
Adenosine and Forskolin Inhibit Platelet Aggregation by Collagen but not the Proximal Signalling Events.
Topics: Adenosine; Adenosine Monophosphate; Adenosine-5'-(N-ethylcarboxamide); Adenylyl Cyclases; Blood Platelets; Carrier Proteins; Cells, Cultured; Colforsin; Collagen; Cyclic AMP; Feedback, Physiological; Humans; Indomethacin; Peptides; Platelet Aggregation; Platelet Membrane Glycoproteins; Receptor, Adenosine A2A; Signal Transduction; Thromboxane B2 | 2019 |
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Coronary Artery Disease; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Preliminary Experience with Cangrelor for Endovascular Treatment of Challenging Intracranial Aneurysms.
Topics: Adenosine Monophosphate; Aneurysm, Ruptured; Aspirin; Cerebral Angiography; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Stents | 2020 |
Anticoagulation in Patients With Heparin-Induced Thrombocytopenia Antibodies: New Armamentarium for an Individually Tailored Approach in Cardiac Surgery.
Topics: Adenosine Monophosphate; Anticoagulants; Cardiac Surgical Procedures; Heparin; Humans; Thrombocytopenia | 2019 |
Cardiac Surgery Successfully Managed With Cangrelor in a Patient With Persistent Anti-PF4/Heparin Antibodies 8 Years After Heparin-Induced Thrombocytopenia.
Topics: Adenosine Monophosphate; Anticoagulants; Cardiac Surgical Procedures; Female; Follow-Up Studies; Forecasting; Heparin; Humans; Middle Aged; Platelet Aggregation Inhibitors; Platelet Factor 4; Postoperative Complications; Thrombocytopenia | 2019 |
Heparin-Induced Thrombocytopenia and Cardiac Surgery: Can We Do It All With Cangrelor?
Topics: Adenosine Monophosphate; Cardiopulmonary Bypass; Heparin; Humans; Kidney Failure, Chronic; Thrombocytopenia | 2019 |
Cangrelor bridging strategy for liver damage after mechanical chest compression.
Topics: Adenosine Monophosphate; Cardiopulmonary Resuscitation; Coronary Angiography; Electrocardiography; Female; Humans; Liver; Middle Aged; Platelet Aggregation Inhibitors; Thrombelastography; Ultrasonography; Ventricular Fibrillation; Ventricular Function, Left | 2019 |
Use of cangrelor during venoarterial extracorporeal membrane oxygenation following percutaneous coronary intervention.
Topics: Adenosine Monophosphate; Aged; Extracorporeal Membrane Oxygenation; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies | 2020 |
In Response.
Topics: Adenosine Monophosphate; Cardiopulmonary Bypass; Heparin; Humans; Kidney Failure, Chronic; Thrombocytopenia | 2019 |
Who was the culprit? Non-ST-elevation acute coronary syndrome treated with percutaneous coronary intervention and cangrelor infusion.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Combined Modality Therapy; Electrocardiography; Female; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2019 |
Evaluation of the Newly Developed Adenosine Diphosphate-Induced Platelet Aggregation Level System in Aggregometer on Automated Coagulation Analyzer.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Coagulation Tests; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet-Rich Plasma; Reproducibility of Results | 2019 |
Hypoxia Modulates Platelet Purinergic Signalling Pathways.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adolescent; Adult; Altitude; Blood Platelets; Cell Adhesion Molecules; Cohort Studies; Female; Humans; Hypoxia; Male; Microfilament Proteins; Oxygen; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet-Rich Plasma; Receptors, Purinergic; Receptors, Thrombin; Signal Transduction; Young Adult | 2020 |
Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y
Topics: Adenosine Monophosphate; Drug Resistance; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P1 Receptor Agonists; Receptors, Purinergic P2Y12; Thrombosis | 2019 |
Use of Intravenous Cangrelor as Antiplatelet Bridge Therapy in a Patient Undergoing Esophageal Dilation Procedure.
Topics: Adenosine Monophosphate; Dilatation; Drug-Eluting Stents; Esophagus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists | 2020 |
Use of a novel antiplatelet agent cangrelor in an infant supported with a ventricular assist device.
Topics: Adenosine Monophosphate; Fontan Procedure; Heart-Assist Devices; Humans; Hypoplastic Left Heart Syndrome; Infant; Male; Norwood Procedures; Palliative Care; Platelet Aggregation Inhibitors; Thromboembolism; Treatment Outcome; Ventricular Dysfunction | 2020 |
Platelet Adhesion and Thrombus Formation in Microchannels: The Effect of Assay-Dependent Variables.
Topics: Adenosine Monophosphate; Aspirin; Blood Platelets; Collagen; Cyclooxygenase Inhibitors; Humans; Male; Microfluidics; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Young Adult | 2020 |
Impact of Cangrelor on Coronary Thrombus: Optical Coherence Tomography Assessment.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Tomography, Optical Coherence; Treatment Outcome | 2020 |
Cangrelor use in a 6-year-old patient undergoing complex percutaneous coronary intervention after post-surgical myocardial infarction.
Topics: Adenosine Monophosphate; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention | 2020 |
Potential and Limitations of the New P2Y12 Inhibitor, Cangrelor, in Preventing Heparin-Induced Platelet Aggregation During Cardiac Surgery: An In Vitro Study.
Topics: Adenosine Monophosphate; Anticoagulants; Cardiac Surgical Procedures; Heparin; Humans; Platelet Aggregation; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12 | 2020 |
Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice.
Topics: Adenosine Monophosphate; Animals; Bleomycin; CD40 Antigens; Cytokines; Disease Models, Animal; Inflammation Mediators; Lung; Male; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Neutrophils; Platelet Activation; Platelet Aggregation Inhibitors; Pulmonary Fibrosis | 2020 |
Efficacy of Cangrelor as Bridging Therapy Post PCI.
Topics: Adenosine Monophosphate; Aged; Aspirin; Colectomy; Colonic Neoplasms; Drug-Eluting Stents; Factor Xa Inhibitors; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridones; Thrombosis; Ticagrelor | 2020 |
Cangrelor and Heparin for Pulmonary Thromboendarterectomy in Heparin-Induced Thrombocytopenia.
Topics: Adenosine Monophosphate; Adult; Endarterectomy; Fibrinolytic Agents; Heparin; Humans; Male; Platelet Aggregation Inhibitors; Pulmonary Embolism; Thrombocytopenia | 2020 |
Cangrelor and Stenting in Acute Ischemic Stroke : Monocentric Case Series.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Brain Ischemia; Female; Humans; Ischemic Stroke; Male; Middle Aged; Retrospective Studies; Stents; Thrombectomy; Treatment Outcome | 2021 |
Ticagrelor Prevents Endothelial Cell Apoptosis through the Adenosine Signalling Pathway in the Early Stages of Hypoxia.
Topics: Adenosine; Adenosine Monophosphate; Apoptosis; Biomarkers; Cell Hypoxia; Extracellular Space; Human Umbilical Vein Endothelial Cells; Humans; Nitric Oxide Synthase; Phosphatidylinositol 3-Kinases; Prostaglandin-Endoperoxide Synthases; Receptors, Purinergic P1; RNA, Messenger; Signal Transduction; Stress, Physiological; Ticagrelor | 2020 |
Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Clopidogrel; Endovascular Procedures; Female; Humans; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Self Expandable Metallic Stents; Stroke; Subarachnoid Hemorrhage; Ticagrelor; Treatment Outcome | 2021 |
Cangrelor-supported primary percutaneous coronary intervention in a patient with cardiogenic shock due to left main acute occlusion.
Topics: Adenosine Monophosphate; Coronary Occlusion; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Treatment Outcome | 2020 |
Cangrelor dose titration using platelet function testing during cerebrovascular stent placement.
Topics: Adenosine Monophosphate; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents | 2021 |
Commentary: "The Enemy of My Enemy Is My Friend"-The Saga of Platelet Quiescence in Heparin-Induced Thrombocytopenia Continues.
Topics: Adenosine Monophosphate; Cardiopulmonary Bypass; Heparin; Humans; Thrombocytopenia | 2020 |
Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.
Topics: Adenosine Monophosphate; Adult; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug-Eluting Stents; Humans; Hydroxyurea; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; ST Elevation Myocardial Infarction; Thrombocythemia, Essential; Treatment Outcome | 2020 |
Prevention of P2 Receptor-Dependent Thrombocyte Activation by Pore-Forming Bacterial Toxins Improves Outcome in A Murine Model of Urosepsis.
Topics: Adenosine Monophosphate; Animals; Bacterial Toxins; Blood Platelets; Deoxyadenine Nucleotides; Disease Models, Animal; Escherichia coli Proteins; Hemolysin Proteins; Humans; Male; Mice, Inbred BALB C; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Sepsis; Treatment Outcome; Urinary Tract Infections; Uropathogenic Escherichia coli | 2020 |
Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).
Topics: Adenosine Monophosphate; Amino Acid Sequence; Betacoronavirus; Binding Sites; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; Enzyme Inhibitors; Folic Acid; Genome, Viral; Glucosides; Humans; Methyltransferases; Molecular Docking Simulation; Mutation; Pandemics; Pneumonia, Viral; RNA Helicases; SARS-CoV-2; Stilbenes; Vidarabine; Viral Nonstructural Proteins | 2020 |
Use of Cangrelor in Cervical and Intracranial Stenting for the Treatment of Acute Ischemic Stroke: A "Real Life" Single-Center Experience.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Carotid Artery, Internal; Cerebral Hemorrhage; Endovascular Procedures; Female; Humans; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Thrombectomy; Treatment Outcome | 2020 |
Cangrelor PK/PD analysis in post-operative neonatal cardiac patients at risk for thrombosis.
Topics: Adenosine Monophosphate; Anticoagulants; Humans; Infant, Newborn; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thrombosis; Venous Thromboembolism | 2021 |
The use of cangrelor in neurovascular interventions: a multicenter experience.
Topics: Adenosine Monophosphate; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Treatment Outcome | 2021 |
Antiplatelet Therapy During Emergent Extracranial Internal Carotid Artery Stenting: Comparison of Three Intravenous Antiplatelet Perioperative Strategies.
Topics: Abciximab; Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Drug Administration Schedule; Emergencies; Endovascular Procedures; Female; Humans; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Stents; Time Factors; Treatment Outcome | 2021 |
Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2021 |
The Use of Cangrelor Infusions After Endovascular Aortic Repair With Prophylactic Lumbar Drain Placement.
Topics: Adenosine Monophosphate; Drainage; Endovascular Procedures; Humans; Retrospective Studies; Risk Assessment; Treatment Outcome | 2021 |
Clinical Use of Cangrelor After Percutaneous Coronary Intervention in Patients Requiring Mechanical Circulatory Support.
Topics: Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Retrospective Studies; Shock, Cardiogenic | 2021 |
Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty.
Topics: Adenosine Monophosphate; Aged; Anxiety; Chest Pain; Coronary Angiography; Coronary Occlusion; Drug Substitution; Drug-Eluting Stents; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Electrocardiography; Humans; Inferior Wall Myocardial Infarction; Male; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome; Withholding Treatment | 2021 |
Letter by Angiolillo et al Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial".
Topics: Adenosine Monophosphate; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial".
Topics: Adenosine Monophosphate; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
With regard to "The use of cangrelor in neurovascular interventions: a multicenter experience".
Topics: Adenosine Monophosphate; Humans; Platelet Aggregation Inhibitors | 2021 |
Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus.
Topics: Adenosine Monophosphate; Adenosine-5'-(N-ethylcarboxamide); Adult; Animals; Antithrombins; Blood Pressure; Blood-Brain Barrier; Chlorides; Diastole; Female; Ferric Compounds; Fibrinogen; Humans; Laser-Doppler Flowmetry; Male; Mice, Inbred C57BL; Permeability; Platelet Activation; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P1 Receptor Agonists; Purinergic P2Y Receptor Antagonists; Systole; Thrombosis | 2021 |
Use of intravenous cangrelor and stenting in acute ischemic stroke interventions: a new single center analysis and pooled-analysis of current studies.
Topics: Adenosine Monophosphate; Brain Ischemia; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Stents; Stroke; Treatment Outcome | 2021 |
Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Female; Gastrointestinal Hemorrhage; Hematocrit; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ST Elevation Myocardial Infarction | 2021 |
Ginsenosides Rb2 and Rd2 isolated from
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Animals; Blood Platelets; Flowers; Ginsenosides; Humans; Mice; Mice, Inbred C57BL; Panax notoginseng; Phosphatidylinositol 3-Kinases; Plants, Medicinal; Platelet Aggregation; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-akt; Saponins; Signal Transduction; Thrombosis | 2021 |
Clinical use of cangrelor: a real-world multicenter experience from South Italy.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
A Multicenter Preliminary Study of Cangrelor following Thrombectomy Failure for Refractory Proximal Intracranial Occlusions.
Topics: Adenosine Monophosphate; Humans; Prospective Studies; Retrospective Studies; Stroke; Thrombectomy; Treatment Outcome | 2021 |
Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17.
Topics: Acute Lung Injury; Adenosine Monophosphate; Animals; Cecum; Disease Models, Animal; Ligation; Mice; Mice, Inbred C57BL; Punctures; Purinergic P2Y Receptor Antagonists; Sepsis | 2021 |
Characterization of antiplatelet response to low-dose cangrelor utilizing platelet function testing in neuroendovascular patients.
Topics: Adenosine Monophosphate; Endovascular Procedures; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Stents | 2021 |
"Tailored" antiplatelet bridging therapy with cangrelor: moving toward personalized medicine.
Topics: Adenosine Monophosphate; Humans; Platelet Aggregation Inhibitors; Precision Medicine; Purinergic P2Y Receptor Antagonists | 2022 |
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
Topics: Adenosine Monophosphate; Blood Platelets; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2021 |
Safety of Intravenous Cangrelor Administration for Antiplatelet Bridging in Hospitalized Patients: A Retrospective Study.
Topics: Adenosine Monophosphate; Adolescent; Blood Platelets; Humans; Infusions, Intravenous; Platelet Aggregation Inhibitors; Retrospective Studies | 2021 |
Curcumin by activation of adenosine A
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Curcuma; Curcumin; Cyclic AMP-Dependent Protein Kinases; Drug Synergism; Gene Expression Regulation; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Plant Extracts; Platelet Activation; Platelet Aggregation Inhibitors; Primary Cell Culture; Purinergic P2Y Receptor Antagonists; Receptor, Adenosine A2A; Receptors, Purinergic P2Y12; Signal Transduction | 2022 |
The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?
Topics: Adenosine Monophosphate; Humans; Platelet Aggregation; ST Elevation Myocardial Infarction; Treatment Outcome | 2022 |
Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?
Topics: Adenosine Monophosphate; Humans; Platelet Aggregation; ST Elevation Myocardial Infarction; Treatment Outcome | 2022 |
Perioperative cangrelor in patients with recent percutaneous coronary intervention undergoing liver transplantation: A case series.
Topics: Adenosine Monophosphate; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Liver Transplantation; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2022 |
Insulin-like Growth Factor 1 Promotes Cell Proliferation by Downregulation of G-Protein-Coupled Receptor 17 Expression via PI3K/Akt/FoxO1 Signaling in SK-N-SH Cells.
Topics: Adenosine Monophosphate; Cell Line; Cell Proliferation; Chromones; Down-Regulation; Forkhead Box Protein O1; Gene Knockout Techniques; Humans; Insulin-Like Growth Factor I; Lentivirus; Morpholines; Neurons; Phosphatidylinositol 3-Kinases; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Quinolones; Receptors, G-Protein-Coupled; RNA, Small Interfering; Signal Transduction | 2022 |
Safety and Efficacy of Periprocedural Bridging With Cangrelor Versus Eptifibatide.
Topics: Adenosine Monophosphate; Eptifibatide; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Treatment Outcome | 2022 |
Cangrelor Use Patterns and Transition to Oral P2Y
Topics: Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Treatment Outcome | 2022 |
Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Adult; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
Letter by Zaghloul et al Regarding Article, "Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX".
Topics: Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
Response by Cavender et al to Letter Regarding Article, "Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX".
Topics: Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Treatment Outcome | 2022 |
Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry.
Topics: Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Registries; Treatment Outcome | 2023 |
Dual antiplatelet therapy with aspirin and cangrelor and spinal anesthesia for a urological procedure.
Topics: Adenosine Monophosphate; Anesthesia, Spinal; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors | 2023 |
Long-Term Cangrelor Administration in Neurology Intensive Care: A Case Series.
Topics: Adenosine Monophosphate; Critical Care; Humans; Neurology; Purinergic P2Y Receptor Antagonists | 2023 |
Evaluation of Cangrelor Use After Percutaneous Coronary Intervention in Patients With Mechanical Circulatory Support.
Topics: Adenosine Monophosphate; Adolescent; Cohort Studies; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Thrombosis; Treatment Outcome | 2023 |
Aspiration Thrombectomy With and Without Cangrelor During Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Coronary Thrombosis; Humans; Percutaneous Coronary Intervention; Thrombectomy; Treatment Outcome | 2023 |